Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

Emma Guttman-Yassky, MD, PhD,[a,b] Robert Bissonnette, MD,[c] Benjamin Ungar, MD,[a,b] Mayte Suárez-Fariñas, PhD,[a,b,d] Marius Ardeleanu, MD,[e] Hitokazu Esaki, MD, PhD,[f] Maria Suprun, MSc,[d] Yeriel Estrada, BSc,[a] Hui Xu, MSc,[a] Xiangyu Peng, MSc,[a] Jonathan I. Silverberg, MD, PhD, MPH,[g] Alan Menter, MD,[h] James G. Krueger, MD, PhD,[b] Rick Zhang, PhD,[e] Usman Chaudhry, BS,[e] Brian Swanson, PhD,[i] Neil M. H. Graham, MD, MPH,[e] Gianluca Pirozzi, MD, PhD,[i] George D. Yancopoulos, MD, PhD,[e] and Jennifer D. D. Hamilton, PhD[e] *New York and Tarrytown, NY; Montreal, Quebec, Canada; Fukuoka, Japan; Chicago, Ill; Dallas, Tex; and Bridgewater, NJ*

Background: Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.

Objective: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD).

Methods: Skin biopsy specimens and blood were evaluated from 54 patients randomized 1:1 to weekly subcutaneous doses of 200 mg of dupilumab or placebo for 16 weeks.

Results: Dupilumab (vs placebo) significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype (weeks 4–16). Mean improvements in a meta-analysis–derived AD transcriptome (genes differentially expressed between lesional and nonlesional skin) were 68.8% and 110.8% with dupilumab and −10.5% and 55.0% with placebo (weeks 4 and 16, respectively; $P < .001$). Dupilumab significantly reduced expression of genes involved in type 2 inflammation (*IL13*, *IL31*, *CCL17*, *CCL18*, and *CCL26*), epidermal hyperplasia (keratin 16 *[K16]* and *MKi67*), T cells, dendritic cells (*ICOS*, *CD11c*, and *CTLA4*), and T_H17/T_H22 activity (*IL17A*, *IL-22*, and *S100As*) and concurrently increased expression of epidermal differentiation, barrier, and lipid metabolism genes (filaggrin *[FLG]*, loricrin *[LOR]*, claudins, and *ELOVL3*). Dupilumab reduced lesional epidermal thickness versus placebo (week 4, $P = .001$; week 16, $P = .0002$). Improvements in clinical and histologic measures correlated significantly with modulation of gene expression. Dupilumab also significantly suppressed type 2 serum biomarkers, including CCL17, CCL18, periostin, and total and allergen-specific IgEs.

Conclusion: Dupilumab-mediated inhibition of IL-4/IL-13 signaling through IL-4 receptor α blockade significantly and

From the Departments of [a]Dermatology and [d]Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York; [b]the Laboratory for Investigative Dermatology, Rockefeller University, New York; [c]Innovaderm Research, Montreal; [e]Regeneron Pharmaceuticals, Tarrytown; [f]the Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka; [g]the Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago; [h]the Department of Dermatology, Baylor University Medical Center, Dallas; and [i]Sanofi, Bridgewater.

Research was sponsored by Sanofi and Regeneron Pharmaceuticals. Editorial assistance was funded by Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of potential conflict of interest: E. Guttman-Yassky has been an investigator for AbbVie, Celgene, Eli Lilly, GlaxoSmithKline, Regeneron-Sanofi, Leo Pharma, Pfizer, Galderma, and Glenmark; has been a consultant for Abbvie, Anacor, Eli Lilly, Galderma, GlaxoSmithKline, Leo Pharma, Menlo Therapeutics, Kiniksa, Pfizer, Realm, Regeneron-Sanofi, Asana Biosciences, DBV, Kyowa, Daiichi Sankyo, Glenmark, Novartis, and Dermira; and has received grants from Regeneron/Sanofi, Pfizer, Galderma, Janssen, Celgene, Novartis, Dermira, AbbVie, Innovaderm, and Leo Pharma. R. Bissonnette has been an investigator, consultant, advisory board member, and speaker and/or receives honoraria from Aquinox Pharma, Antiobix, Asana, Astellas, Brickell Biotech, Dermavant, Dermira, Dignity Sciences, Galderma, Glenmark, GlaxoSmithKline-Stiefel, Hoffman-LaRoche Ltd, Leo Pharma, Neokera, Pfizer, Regeneron, and Vitae and is also a shareholder of Innovaderm Research. M. Suárez-Fariñas has been an investigator for Pfizer, Quorum, Regeneron, and Genisphere and a consultant for DBV and NEA. M. Ardeleanu, R. Zhang, U. Chaudhry, N. M. H. Graham, G. D. Yancopoulos, and J. D. D. Hamilton are employees and shareholders of Regeneron Pharmaceuticals. J. I. Silverberg has been an investigator for AbbVie, Celgene, Chugai, Eli Lilly, GlaxoSmithKline, and Regeneron-Sanofi; a consultant for AbbVie, Anacor, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Leo, Menlo, Kiniksa, Pfizer, Realm, and Regeneron-Sanofi; and a speaker for Regeneron-Sanofi. A. Menter has been an advisory board participant, consultant, investigator, and speaker for and received grants and honoraria from Abbvie, Amgen, Janssen Biotech, and LEO Pharmaceuticals; has been an advisory board participant, consultant, and investigator for and received grants and honoraria from Allergan; has been an advisory board participant and investigator for and received grants and honoraria from Boehringer Ingelheim; has been a consultant and investigator for and received grants and honoraria from Novartis, Pfizer, and XenoPort; has been an investigator for and received grants from Anacor, Celgene, Dermira, Merck, Neothetics, Regeneron Pharmaceuticals, and Symbio/Maruho; has been an advisory board participant, consultant, and investigator for and received honoraria from Eli-Lilly; and has been a consultant for and received honoraria from Galderma and Vitae. J. G. Krueger has been a consultant for and received grants paid to his institution by Amgen, BMS, Boehringer, Dermira, Innovaderm, Janssen, Kadmon, Kyowa, Lilly, Merck, Novartis, Paraxel, and Pfizer; has been a consultant for and recipient of personal fees from AbbVie, Baxter, BiogenIdec, Delenex, Kineta, Sanofi, Serono, and Xenoport; and has been an investigator for Regeneron Pharmaceuticals. B. Swanson and G. Pirozzi are employees and might hold stock and/or stock options in Sanofi. The rest of the authors declare that they have no relevant conflicts of interest.

ClinicalTrials.gov identifier: NCT01979016.

Received for publication December 22, 2017; revised July 19, 2018; accepted for publication August 14, 2018.

Available online September 5, 2018.

Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Medical Center, 5 East 98th St, New York, NY 10029. E-mail: Emma.Guttman@mountsinai.org.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749

© 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.jaci.2018.08.022

progressively improved disease activity, suppressed cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation, and reversed AD-associated epidermal abnormalities. (J Allergy Clin Immunol 2019;143:155-72.)

Key words: *Atopic dermatitis, IL-4 receptor α inhibition, dupilumab, transcriptome, gene expression, skin, type 2 inflammation, epidermal pathology*

Abbreviations used

AD:	Atopic dermatitis
CsA:	Cyclosporin A
DC:	Dendritic cell
EASI:	Eczema Area and Severity Index
ECP:	Eosinophilic cationic protein
EDC:	Epidermal differentiation complex
ET:	Epidermal thickness
FCH:	Fold change
FDR:	False discovery rate
FLG:	Filaggrin
IL-4Rα:	IL-4 receptor α
K16:	Keratin 16
LOR:	Loricrin
MADAD:	Meta-analysis–derived atopic dermatitis
NB-UVB:	Narrow-band UVB
PARC:	Pulmonary and activation-regulated chemokine
qRT-PCR:	Quantitative real-time PCR
SCORAD:	SCORing Atopic Dermatitis
TEAE:	Treatment-emergent adverse event

Atopic dermatitis (AD) is a common inflammatory skin disease of increasing prevalence that affects 3% to 10% of adults and 10% to 20% of children globally.[1-5] The disease is moderate to severe in up to one third of patients, many of whom require systemic treatment.[6,7] The profound symptom burden, systemic inflammation, and comorbidities in patients with moderate-to-severe AD[8-15] have a substantial effect on the quality of life of patients and their families and present a large burden to health care systems.[16-19]

Therapeutic options are limited for patients with moderate-to-severe AD who had an inadequate response to topical treatments. They include phototherapy (narrow-band UVB [NB-UVB] or UVA1) and immunosuppressants (oral corticosteroids, cyclosporin A [CsA], and others),[1-5,7,20] which have variable efficacy and are associated with multiple adverse effects on long-term use. Therefore there has been a large unmet need for safe and effective treatments for this patient population.

Dupilumab is the first targeted biologic agent approved in the European Union, United States, Japan, and other countries for the treatment of adults with inadequately controlled moderate-to-severe AD. It is a fully human VelocImmune-derived mAb[21,22] targeting IL-4 receptor α (IL-4Rα), the shared subunit of the type 2 cytokines IL-4 and IL-13, inhibiting signaling of both cytokines. In clinical trials dupilumab consistently showed robust efficacy and acceptable safety in adults with moderate-to-severe AD, asthma, chronic rhinosinusitis with nasal polyposis, or eosinophilic esophagitis,[23-34] supporting the notion that these atopic disorders share a type 2–centered pathogenesis.

Although preliminary data suggest that other type 2 antagonists targeting IL-13 or IL-31 receptor A might be beneficial in patients with AD,[35-37] these effects seem less robust than those of dupilumab, suggesting dual inhibition of IL-4 and IL-13 might be necessary for optimal control of moderate-to-severe AD. The limited efficacy of other type 2 immune inhibitors, such as mepolizumab (anti–IL-5) and omalizumab (anti-IgE), also supports IL-4 and IL-13 as critical mediators of AD pathogenesis.[38-43] Targeting other pathways, such as the T_H17/IL-23 or T_H22 pathways, with ustekinumab (anti–IL-12/23 p40) or fezakinumab/ILV-094 (anti–IL-22) has been less efficacious relative to what has been observed in dupilumab AD trials to date.[44,45]

Scientific evidence supports the view of AD as a systemic immune-driven disease similar to psoriasis, another common inflammatory skin disease.[7-9,11,23,46-49] Both diseases are characterized by induction of polar cytokine pathways, with psoriasis viewed primarily as T_H17/IL-23 driven, whereas type 2 pathways predominate in patients with AD. Signals of the T_H22, T_H17, and T_H1 axes are also observed in patients with AD, but their role in pathogenesis is not proved.[50-53]

AD and psoriasis also have significant epidermal alterations, including increased epidermal hyperplasia and upregulated epidermal expression of antimicrobial proteins (S100A7/S100A8/S100A9). AD is uniquely characterized by suppression of terminal differentiation markers in lesional and nonlesional skin.[7,54,55] In patients with psoriasis, increased understanding of pathogenic pathways led to rapid development of multiple biotherapeutics,[7,56-66] which in turn demonstrated the relation between immune suppression and reversal of epidermal pathology.[58,60,61,67]

The cytokines IL-4 and IL-13 were suggested to have direct effects on the epidermis in patients with AD, including (1) inhibition of terminal differentiation with potential for feedback hyperplasia (keratinocyte hyperproliferation),[1,3,57,68-72] (2) induction of spongiosis,[73] (3) inhibition of lipid synthesis,[73] (4) inhibition of synthesis of antimicrobial peptides,[74-77] and (5) promotion of binding and colonization by *Staphylococcus aureus*.[78] IL-4 and IL-13 have also been suggested to induce type 2 activation and differentiation of dendritic cells (DCs), promote B-cell activation and IgE class-switching, and recruit eosinophils.[79-81]

Systemic upregulation of type 2 inflammation in patients with AD has also been demonstrated by increased serum concentrations of CCL17 (thymus and activation-regulated chemokine [TARC]), CCL18 (pulmonary and activation-regulated chemokine [PARC]), eosinophilic cationic protein (ECP), and periostin, which correlated with AD severity.[82-89]

Most patients with AD (or other atopic diseases) have increased IgE levels and antigen-specific IgE sensitization, as demonstrated by increased serum concentrations of various IgEs specific to common allergens (eg, house dust mite, staphylococcal enterotoxins, cat and dog dander, *Cladosporium* species, and grass).[90-95] Nevertheless, although higher concentrations of total and specific IgEs have been associated with higher clinical AD severity at baseline,[11,90] treatment with broad-target agents, such as CsA or phototherapy, does not consistently reduce IgE levels, an observation suggesting that these treatments do not adequately suppress IL-4 and IL-13 activity[47,96,97] and might even lead to increased IgE levels.[98]

Previously, we reported that in a short (4-week) phase 1b trial, inhibition of type 2 inflammation with dupilumab modifies

molecular mechanisms in skin of patients with AD, thus establishing a central pathogenic role for IL-4 and IL-13.[46,99] However, that trial was conducted in only a small number of patients across several dupilumab dose and placebo groups, and it lacked cellular correlates and long-term evaluations of genomic and cellular markers.[46]

We now present results from a larger 16-week study evaluating the efficacy and safety of dupilumab in patients with moderate-to-severe AD, with a focus on the effect of treatment on molecular and cellular phenotypes of lesional and nonlesional skin biopsy specimens and on systemic type 2 biomarkers. Treatment with dupilumab (compared with placebo) progressively improved clinical AD severity and resulted in molecular suppression of AD genomic and cellular measures of inflammation and systemic type 2 biomarkers as early as week 4, and continued improvement beyond 16 weeks of treatment included reversal of AD-associated epidermal pathology.

METHODS

Study design

This was a randomized, placebo-controlled, double-blind, phase 2 trial (ClinicalTrials.gov: NCT01979016) conducted at 5 medical centers in the United States and Canada to assess the efficacy and safety of dupilumab compared with placebo in patients with moderate-to-severe AD. Molecular and cellular phenotypes of lesional and nonlesional skin and pharmacodynamic effects on serum type 2 biomarkers were evaluated. Patients (54/66 screened) were randomized 1:1 to weekly subcutaneous injections of 200 mg of dupilumab or placebo after a 400 mg loading dose or placebo on day 1, for a total of 16 weeks. The 16-week treatment period was followed by a 16-week safety follow-up period (until week 32).

The study was conducted in accordance with current US Food and Drug Administration regulations and guidelines and International Conference on Harmonization guidelines on Good Clinical Practice; all participants provided written informed consent under institutional review board approved protocols before participation (additional information is available in the Methods section in this article's Online Repository at www.jacionline.org).

Patients

Eligible patients were 18 years old or older, had moderate-to-severe AD (Eczema Area and Severity Index [EASI] score ≥16 at baseline) chronically for 3 or more years, and had an inadequate response to topical medications within 6 months before screening. Use of topical corticosteroids or calcineurin antagonists was prohibited 1 week before and during the study. Patients were allowed to use only bland topical emollients during the study. Oral immunosuppressant agents and phototherapy were prohibited for 4 weeks before and during the trial (see the Methods section in this article's Online Repository for additional details).

Study end points

Efficacy end points included mean percentage change from baseline to week 16 in EASI scores (primary end point) and peak pruritus numeric rating scale scores and proportions of patients achieving reductions of 50% or greater, 75% or greater, and 90% or greater from baseline in EASI and SCOring Atopic Dermatitis (SCORAD) scores at week 16. Additional efficacy end points included mean (percentage) changes from baseline to week 16 in total SCORAD score, Patient-Oriented Eczema Measure score, and total Global Individual Signs Score and Global Individual Signs Score components. All efficacy end points are reported in detail in Table E1 in this article's Online Repository at www.jacionline.org.

Safety was assessed from baseline through week 32 based on the incidence of treatment-emergent adverse events (TEAEs; see Table E2 in this article's Online Repository at www.jacionline.org). Exploratory assessments included genomic changes in active AD lesions and changes in the AD transcriptome defined by gene expression differences between lesional and nonlesional skin and assessment of effects of dupilumab treatment on epidermal hyperplasia, as defined by changes in epidermal thickness (ET), keratin 16 (K16) expression or Ki67$^+$ cells, and inflammatory cells in tissues.[46-48,100] An exploratory assessment was also conducted of treatment-related changes in the serum biomarkers CCL17, CCL18, periostin, ECP, total IgE, and allergen-specific IgEs (gray alder, *Alternaria tenuis*, Bermuda grass, silver birch, cat dander, *Cladosporium* species, German cockroach, *Dermatophagoides farinae*, dog dander, elm, Johnson grass, white oak, ragweed, sage mugwort, Timothy grass, white ash, staphylococcal enterotoxin A, and staphylococcal enterotoxin B).

Assessments

Biopsy and blood collection. Biopsy specimens (6 mm) were collected from lesional and nonlesional skin at baseline and at weeks 4 (lesional skin only) and 16. Blood samples were collected at similar time points. Posttreatment biopsy specimens were taken from the same location as pretreatment biopsy specimens approximately 1 cm from prior biopsy scars. All skin and blood analyses were performed while investigators were blinded to treatment allocation.

Immunohistochemistry. Immunohistochemistry was performed on frozen OCT-embedded cryostat tissue sections by using purified mouse anti-human mAbs, as previously described (see Table E3 in this article's Online Repository at www.jacionline.org).[48,54] ET was measured by using computer-assisted image analysis software of hematoxylin and eosin–stained sections (ImageJ 1.42 software; National Institutes of Health, Bethesda, Md), as previously described.[47]

Quantitative real-time PCR and gene-array analysis. RNA was extracted, followed by hybridization to Affymetrix Human U133Plus 2.0 gene arrays (Affymetrix, Santa Clara, Calif) or by using quantitative real-time PCR (qRT-PCR), as previously described (see Table E4 in this article's Online Repository at www.jacionline.org).[48,100] Expression of target genes was determined by using qRT-PCR and normalized to the housekeeping gene human acidic ribosomal protein for analyses.

Circulating biomarkers. Levels of serum total and allergen-specific IgE and ECP were measured by using the ImmunoCAP method.[101,102] Only patients with positive results (≥0.1 kU/L) for allergen-specific IgEs at baseline were included in IgE analyses. Serum CCL17 and CCL18 levels were measured by using Quantikine ELISA kits (R&D Systems, Minneapolis, Minn), and periostin levels were measured by using the R&D Systems DuoSet ELISA kit.

Statistical analyses

Sample size was determined to achieve 79% power to detect a 40% difference between dupilumab and placebo with respect to percentage change in EASI score from baseline to week 16, assuming the common SD is 50% with a 2-sided test at the .05 significance level.

All clinical and circulating biomarker analyses were performed by using SAS (SAS Institute, Cary, NC). Analysis of secondary efficacy end points and exploratory variables were not adjusted for multiplicity, and thus nominal *P* values are provided. Additional details of the analyses performed are reported in the Methods section in this article's Online Repository.

RNA, serum, and correlation analyses were performed in Bioconductor R packages (open source software available from www.bioconductor.org). Linear mixed-effect models were used to assess treatment changes in $\log_2$-transformed qRT-PCR measurements (normalized to human acidic ribosomal protein), with tissue (lesional/nonlesional) and its interaction with time as a fixed factor. qRT-PCR values of less than the limit of detection were imputed as 20% of the minimal value over the limit of detection. Missing values for all mechanistic data were not imputed. The histologic score is a combined score of ET and mRNA expression of K16, as obtained by averaging the z score of both measures.

Quality control of microarrays used standard metrics and R package microarray quality control. Images were scrutinized for spatial artifacts by using Harshlight (Bioconductor).[103] Expression measures were obtained by using the GC Robust Multi-array Average algorithm.[104] Probe sets with expression of greater than 3 in at least 15 samples were kept for analyses.

Expression values were modeled by using mixed-effect models, with treatment and time as fixed factors and a random effect for each patient. Fold changes (FCHs) for comparisons of interest were estimated, and hypothesis testing was conducted with contrasts under the general framework for linear models in R *limma* package. *P* values from moderated (paired) *t* tests were adjusted for multiple hypotheses by using the Benjamini-Hochberg procedure, which controls the false discovery rate (FDR).[105] Genes with FDR of less than 0.05 and FCH of 2 or greater were declared differentially expressed. Hierarchical clustering of mean expression profiles was performed with Euclidean distance and a McQuitty agglomeration scheme.[54,104]

AD-associated immune or barrier gene subsets were quantified by using Gene Set Variation Analysis, an unsupervised sample-wise enrichment method that produces a score of activity for a gene subset or pathways for each sample.[106] Modeling was performed by using the same approach described for genes, including adjustment for multiplicity. The association of biomarkers and gene sets with clinical responses was evaluated by using Spearman correlation coefficients. An unsupervised clustering analysis using Spearman correlation and a McQuitty agglomeration scheme is presented.

RESULTS

Patients

Of 66 patients screened, 54 (81.8%) were randomized to receive 200 mg of dupilumab every week (n = 27) or placebo every week (n = 27). Most patients in the placebo (25/27 [92.6%]) and dupilumab (26/27 [96.3%]) groups completed the study to week 16 (see Fig E1 in this article's Online Repository at www.jacionline.org). Baseline demographics and disease characteristics were not statistically different between treatment groups, except for ET of nonlesional skin ($P = .010$, see Table E5 in this article's Online Repository at www.jacionline.org).

Skin biopsy specimens for exploratory analyses were available for analysis from 27 patients in the dupilumab group and from 25 patients in the placebo group. Numbers of lesional and nonlesional samples collected at baseline, week 4, and week 16 from dupilumab- and placebo-treated patients available for analyses are reported in Table E6 in this article's Online Repository at www.jacionline.org. The number of serum samples collected at baseline, week 4, and week 16 from dupilumab- and placebo-treated patients available for analyses are provided in Table E7 in this article's Online Repository at www.jacionline.org.

Efficacy

Dupilumab, compared with placebo, significantly improved measures of clinical efficacy at week 16, including EASI scores ($P < .0001$; see Table E8 and Fig E2, *A*, in this article's Online Repository at www.jacionline.org) and peak pruritus numeric rating scale scores ($P = .003$; see Table E8 and Fig E2, *D*). Proportions of patients with reductions of 50% or greater, 75% or greater, and 90% or greater from baseline in EASI scores at week 16 were also significantly greater with dupilumab than placebo (see Fig E2, *B*). An illustration of clinical improvement with dupilumab in representative patients is shown in Fig E2, *C*. Dupilumab also significantly improved other clinical outcomes relative to placebo, except for the proportions of patients with reductions of 75% or greater and 90% or greater from baseline in SCORAD scores (see Table E8).

Safety

The overall incidence of TEAEs was generally similar in the 2 study groups: 24 (88.9%) patients in the dupilumab group versus 23 (85.2%) patients in the placebo group (see Table E2). No deaths were reported in the study. The incidence of serious TEAEs was numerically greater in the placebo group than in the dupilumab group, whereas the incidence of TEAEs resulting in permanent treatment discontinuation was similar in the 2 treatment groups (see Table E2). The most common TEAEs reported in this study are shown in Table E2.

Suppression of inflammatory cell infiltrates in dupilumab-treated skin

Immunostaining was performed to measure cellular infiltrates of $CD3^+$, $CD8^+$, and $CD1b^+$ T cells; various DC markers, including $CD83^+$, $CD11c^+$, $CD206^+$, $Fc\varepsilon RI^+$, $CD1c^+$, and $CD1a^+$ Langerhans cells; and major basic protein–positive eosinophils in lesional and nonlesional skin after 4 and 16 weeks of treatment (see Fig E3 in this article's Online Repository at www.jacionline.org). Marked and significant reductions in infiltrates at week 16 were only seen with dupilumab, with the exception of major basic protein–positive eosinophils, numbers of which were also reduced with placebo (see Table E9 in this article's Online Repository at www.jacionline.org). As early as week 4, DC markers ($CD11c^+$ and $CD1c^+$ cells) showed significant reductions with dupilumab versus placebo (see Table E9). $Fc\varepsilon RI^+$ cells were significantly reduced from baseline at week 16 with dupilumab ($P < .05$ for mean percentage change from baseline and vs placebo). There were no significant differences between treatment groups in $CD8^+$ or $CD1b^+$ T cells or in $CD83^+$ DCs (see Table E9). Nonlesional skin, which had significantly less increased infiltrates relative to control tissues at baseline, also showed no significant differences (data not shown).

Progressive shift of AD molecular phenotype from lesional to nonlesional

Affymetrix U133Plus 2.0 gene arrays (Affymetrix) were performed to define the AD skin phenotype or transcriptome at baseline (differentially expressed genes between lesional and nonlesional skin). Criteria of FCH of 2 or greater and FDR of less than 0.05 were used. These differentially expressed genes were used to assess the overall effects of dupilumab versus placebo on the AD transcriptome. In samples from patients with AD collected in this study, the baseline transcriptome of lesional versus nonlesional skin was defined by 527 upregulated and 508 downregulated probes in the placebo group and 411 upregulated and 336 downregulated probes in the dupilumab group (Fig 1, *A*).

At week 16, no gene probes in the dupilumab group met the statistical criteria for being differentially regulated, whereas in the placebo group the number of differentially regulated gene probes increased relative to baseline (Fig 1, *A* and *B*). Overall, dupilumab significantly altered gene expression in lesional skin at both weeks 4 and 16 versus baseline; there was no comparable modulation in placebo-treated patients.

Similar genomic changes with dupilumab (vs placebo) were observed after evaluating a recently published, robust, meta-analysis–derived atopic dermatitis (MADAD) transcriptome derived from a meta-analysis of multiple study transcriptomes.[107] Based on the MADAD transcriptome, significantly altered gene expression (vs baseline) was already evident in lesions of dupilumab-treated patients at week 4, with a further shift to a



FIG 1. Transcriptomic changes. **A** and **B,** Numbers of differentially expressed genes *(DEGs)* with criteria of an FCH of greater than 2 and FDR of less than 0.05 upregulated *(Up)* and downregulated *(Down)* at baseline *(W0)* and week 16 *(W16)* in lesional *(LS)* versus nonlesional *(NL)* skin in the placebo and dupilumab groups and number of genes differentially modified in LS skin at week 4 *(W4)* and week 16 versus baseline in the study transcriptome (Fig 1, *A*) and the MADAD transcriptome (Fig 1, *B*). **C,** Heat map of the MADAD transcriptome with comparisons to healthy subjects *(Normal)*. Sample data are ordered at each time point and tissue type by decreasing EASI score (indicated by the *gray scale bar*; *black* indicates highest EASI score, and *white* indicates lowest EASI score). **D,** Overall percentage improvement in the MADAD transcriptome at W4 and W16 is shown. ***$P < .001$ at both time points for dupilumab versus placebo comparison. **E,** Effect of dupilumab on expression of genes upregulated *(red)* or downregulated *(blue)* in lesional versus nonlesional skin in the MADAD transcriptome. *Blue bars* superimposed on the plots represent means ± SEMs.

more nonlesional phenotype at week 16 (red-to-blue or blue-to-red transitions; Fig 1, *C*). At week 16, lesions from dupilumab-treated patients had expression levels similar to those of nonlesional skin. No major changes were seen in lesions from placebo-treated patients at week 4 versus baseline, whereas some changes were noted in placebo-treated AD lesions at



	Week 4 vs. Week 0			Week 16 vs. Week 0		
	Placebo	Dupilumab	TE	Placebo	Dupilumab	TE
CD3E -----:	1.25	−1.37	−1.72	−1.23	−2.08**	−1.69
LCK ------:	1.12	−1.15	−1.29	−1.46	−1.86*	−1.28
IL7R -----:	1.41	−1.34	−1.89	−1.10	−1.80**	−1.64
JAK3 -----:	1.11	−1.35	−1.51	−1.22	−1.77**	−1.46
CD2 ------:	1.46	−1.28	−1.87	−1.16	−2.06*	−1.77
CD3G -----:	1.48	−1.41	−2.09	−1.10	−2.07*	−1.88
CD5 ------:	1.32	−1.56	−2.06	−1.38	−2.59**	−1.88
IL2RA ----:	−1.15	−1.25	−1.09	−1.80	−1.61+	1.12
CD80 -----:	1.07	−1.24	−1.33	−1.33	−1.92*	−1.44
STAT1 ----:	−1.20	−1.61	−1.34	−1.45	−2.16**	−1.48
CD86 -----:	1.07	−1.95*	−2.08	−1.32	−2.56**	−1.95
CXCR4 ----:	1.08	−1.46	−1.58	−1.45	−2.01**	−1.39
CCR5 -----:	1.04	−1.58+	−1.64	−1.28	−1.87**	−1.47
CCL4 -----:	−1.13	−1.26	−1.12	−1.52	−1.80*	−1.19
S100A12 --:	1.51	−5.97**	−9.01+	−5.25	−9.04**	−1.72
IL22 -----:	1.26	−1.93	−2.43	−2.91	−2.55+	1.14
IL19 -----:	−1.10	−1.70	−1.54	−1.45	−2.01+	−1.39
IL23A ----:	1.26	−1.18	−1.49	1.03	−1.54*	−1.59
IL32 -----:	1.07	−1.19	−1.28	−1.04	−1.67*	−1.61
CD3D -----:	1.15	−1.32	−1.53	−1.21	−1.93**	−1.60
ITGB2 ----:	1.04	−1.38	−1.43	−1.28	−1.99**	−1.55
CCL19 ----:	1.00	−1.18	−1.18	−1.01	−1.61+	−1.58
CCL5 -----:	1.13	−1.36	−1.53	−1.16	−1.71+	−1.48
CCR2 -----:	1.13	−1.60+	−1.80	−1.16	−1.87**	−1.61
LCN2 -----:	1.26	−1.88	−2.38	−1.02	−2.78**	−2.74
PI3 ------:	1.29	−2.72**	−3.51+	−1.65	−4.65**	−2.81
CCR1 -----:	1.08	−2.16**	−2.34	−1.22	−3.31**	−2.71
S100A9 ---:	1.10	−3.27**	−3.59	−2.21	−9.95**	−4.50
OASL -----:	1.18	−4.67**	−5.50+	−2.42	−10.20**	−4.21
ITGAX ----:	1.01	−1.93**	−1.95	−1.07	−2.91**	−2.71
CD1B -----:	1.13	−2.93*	−3.31	−1.12	−6.97**	−6.23
CCL17 ----:	1.14	−5.41**	−6.17+	−1.15	−7.85**	−6.80
CCL22 ----:	1.01	−1.61	−1.62	−1.10	−2.63**	−2.39
CXCL1 ----:	1.35	−4.23**	−5.72+	−1.85	−7.93**	−4.28
CCR7 -----:	1.07	−1.43	−1.54	−1.39	−2.23**	−1.61
CXCL3 ----:	−1.10	−1.63	−1.48	−1.29	−2.37**	−1.84
CXCL2 ----:	−1.01	−2.35*	−2.32	−2.28	−3.53**	−1.55
CCL18 ----:	1.20	−5.62**	−6.77**	1.28	−9.32**	−11.90**
MMP12 ----:	1.10	−9.96**	−11.00+	1.01	−49.60**	−50.30**
ITK ------:	1.36	−1.21	−1.65	−1.07	−1.66*	−1.54
CTLA4 ----:	1.57	−1.33	−2.09	−1.08	−3.46**	−3.22
ICOS -----:	1.46	−1.29	−1.89	−1.60	−2.23*	−1.39
CD28 -----:	1.58	−1.10	−1.75	1.23	−2.00*	−2.47
CCL20 ----:	1.60	1.11	−1.44	−1.76	−1.52	1.16
CXCL10 ---:	−1.30	−1.23	1.06	−3.07	−1.58	1.94
CXCL9 ----:	1.11	−1.18	−1.30	−1.44	−1.61	−1.12
IL12RB2 --:	−1.16	−1.58+	−1.36	−1.42	−2.23**	−1.57
CCL1 -----:	−1.73	−2.23**	−1.29	−1.71	−2.34**	−1.36
CCL26 ----:	1.04	−20.30**	−21.00**	−1.12	−46.00**	−41.10**

FIG 2. MADAD immune genes. Heat map of mean expression levels of a curated list of immune genes in the MADAD transcriptome. The table shows gene symbols with signed FCHs at week 4 *(W4)* and week 16 *(W16)* versus week 0 *(W0)*. Treatment effect *(TE)* is the comparison of change in dupilumab versus change in placebo at week 4 or week 16. $+P < .1$, $*P < .05$, and $**P < .01$ (P values are adjusted).

week 16 (Fig 1, *C*, and see Table E10 in this article's Online Repository at www.jacionline.org).

With dupilumab treatment, there were mean genomic improvements in the MADAD transcriptome of 68.8% (73.8% decreases in upregulated genes and 59.7% increases in downregulated genes) at week 4 and 110.8% (120.1% decreases in upregulated genes and 93.7% increases in downregulated genes) at week 16 ($P < .001$ vs placebo; Fig 1, *D*). In placebo-treated patients we observed a worsening of lesional skin by 10.5% to a more lesional molecular phenotype (6.7% increase in upregulated genes and 17.3% decrease in downregulated genes) in the MADAD transcriptome at week 4, with an overall improvement of 55.0% (59.2% decreases in upregulated genes and 47.1% increases in downregulated genes) at week 16 (Fig 1, *D*). Fig 1, *E*, shows the dupilumab-induced reversal of the baseline genomic dysregulation between lesional and nonlesional skin of patients with AD (in both upregulated and downregulated genes) at weeks 4 and 16 versus minimal changes with placebo.

Dupilumab suppression of type 2, T_H17, and T_H22 inflammatory pathways in lesional skin

As measured by using microarray expression profiling, dupilumab showed significant modulation at week 4 and progressive suppression through week 16 of key immune genes in the MADAD transcriptome.[46-48,107] These included genes related to inflammatory proteases (*MMP12*, *SERPINB4 [SCCA1/2]*, *MMP3*, and *MMP1*), DCs (*CD1b*, *ITGAX*/*CD11c*, and *CD1c*), T-cell activation (granzyme B, *ICOS*, and *CCR7*), the type 2 pathway (*CCL26*, *IL13RA2*, *CCL17*, *CCL18*, *CCL13*, *CCL22*, and *DPP4*), the T_H17/T_H22 pathway (*CXCL1*/*CXCL2*, *LCN2*, and *S100A9*/*S100A12*), and negative regulators (*CTLA4*; Fig 2 and see Table E10).



FIG 3. FCHs in inflammatory markers measured by using qRT-PCR. FCHs in inflammatory markers in lesional skin at week 4 *(W4)* and week 16 *(W16)* and at week 16 in nonlesional skin versus baseline. *Black asterisks*, Significance of comparison between placebo and dupilumab; *red asterisks*, significance of comparison with baseline. $+P < .1$, $*P < .05$, $**P < .01$, and $***P < .001$.



	Week 4 vs. Week 0			Week 16 vs. Week 0		
	Placebo	Dupilumab	TE	Placebo	Dupilumab	TE
IL4 ------:	−1.15	1.23	1.42	1.11	1.29	1.16
IL23p19 --:	1.12	−1.12+	−1.26*	1.10	−1.06	−1.17
IL5 ------:	−1.03	1.00	1.03	−1.03	1.14	1.17
CCL20 ----:	1.37	1.48	1.08	−1.17	1.23	1.44
CXCL10 ---:	−1.16	1.01	1.17	−1.80	−1.11	1.62
IL1b -----:	−1.17	1.00	1.17	−1.30	−1.06	1.23
IL31 -----:	1.07	−1.30+	−1.39	−1.18	−1.40*	−1.19
FOXP3 ----:	1.22	1.08	−1.13	1.01	−1.14	−1.15
IL23p40 --:	1.83+	−1.07	−1.96	−1.33	−1.62	−1.22
IFNG -----:	1.30+	−1.08	−1.40+	1.04	1.00	−1.04
IL17A ----:	1.61*	−1.33	−2.14*	1.66+	−1.85**	−3.07**
CCL26 ----:	−1.08	−5.34**	−4.96**	−1.01	−6.70**	−6.62**
CCL13 ----:	1.26	−2.92**	−3.67**	1.28	−4.02**	−5.12**
CCL18 ----:	1.43+	−6.59**	−9.40**	1.26	−9.90**	−12.50**
IL22 -----:	−1.05	−2.22*	−2.11	−1.44	−2.07*	−1.44
LOR ------:	1.07	1.84**	1.71+	2.07**	2.09**	1.01
FLG ------:	1.24	1.45*	1.17	1.69*	1.71**	1.01
CCL17 ----:	1.19	−2.59**	−3.09**	1.09	−2.88**	−3.13**
CXCL1 ----:	1.10	−2.90**	−3.18**	−1.32	−3.97**	−3.00**
MMP12 ----:	−1.13	−6.50**	−5.77**	1.07	−20.10**	−21.40**
IL10 -----:	1.13	−1.49**	−1.68*	1.06	−2.37**	−2.51**
CCL22 ----:	1.02	−1.56*	−1.59+	−1.15	−2.39**	−2.09*
IL13 -----:	1.04	−1.31	−1.37	−1.09	−2.31**	−2.12+
LOR/K16 --:	1.12	7.64**	6.81**	4.95**	12.70**	2.57
FLG/K16 --:	1.28	6.09**	4.75**	4.01**	10.50**	2.61
K16 ------:	−1.03	−4.19**	−4.06**	−2.36**	−6.11**	−2.59*
IL9 ------:	−1.19	−2.69*	−2.26	−2.12	−5.52**	−2.60
S100A7 ---:	1.20	−2.33**	−2.78**	−1.68+	−3.83**	−2.28*
S100A8 ---:	1.22	−3.56**	−4.35**	−2.80**	−7.66**	−2.73*
PI3 ------:	1.15	−3.90**	−4.50**	−2.92**	−6.79**	−2.33
S100A12 --:	1.55	−3.62**	−5.62**	−2.45*	−8.86**	−3.61*

FIG 4. Heat map of genes measured by using qRT-PCR and cellular infiltrates. Heat map of mean gene expressions measured by using qRT-PCR in lesional skin at week 0 *(W0)*, week 4 *(W4)*, and week 16 *(W16)* and nonlesional skin at weeks 0 and 16 in the placebo and dupilumab groups. The table shows FCHs at week 4 and week 16 versus week 0. Treatment effect *(TE)* is the comparison of change in dupilumab versus change in placebo at week 4 and week 16. Expression ratios of FLG/K16 and LOR/K16 are included. $+P < .1$, $*P < .05$, $**P < .01$, and $***P < .001$.

To more accurately quantify low-expressing genes not always captured on microarrays, we also performed qRT-PCR; representative markers of the various immune axes associated with AD were included. Highly significant reductions in mRNA expression of the general inflammatory marker MMP12 were seen in dupilumab- versus placebo-treated lesional and nonlesional skin at both weeks 4 and 16 (Figs 3 and 4). As expected, dupilumab significantly suppressed mRNA expression of genes of type 2 inflammation regulated by IL-4Rα–mediated signaling (Figs 3 and 4 and see Fig E4 in this article's Online Repository at www.jacionline.org). Robust and significant reductions in expression of the type 2–polarizing chemokines CCL13/monocyte chemoattractant protein 4, CCL18/PARC, CCL26/Eotaxin-3, CCL17/TARC, and CCL22/macrophage-derived chemokine were observed in lesional skin at weeks 4 and 16. A reduction of *IL13* gene expression at week 16 ($P < .01$ vs baseline and $P < .10$ vs placebo) was also observed. Dupilumab, but not placebo, reduced expression of the itch-associated cytokine IL-31 ($P < .05$ vs baseline at week 16) and the regulatory cytokine IL-10 ($P < .001$ vs baseline and vs placebo at week 16) in lesional skin (Figs 3 and 4). Progressive suppression of the T_H9 cytokine IL-9 was observed in lesions treated with dupilumab but not placebo ($P < .001$ vs baseline for dupilumab at week 16). No significant changes were noted in expression of the T_H1/IFN-γ markers IFN-γ and CXCL10 in skin from dupilumab-treated patients, as measured by using qRT-PCR. Consistent with array results, dupilumab also significantly suppressed mRNA expression of T_H17- and T_H22-regulated genes in lesional skin, including *IL17A* ($P < .05$ vs placebo at both weeks 4 and 16), *CXCL1* ($P < .001$ vs baseline and $P < .01$ vs placebo), *PI3*, *IL22*, and the IL-17/IL-22–regulated *S100A9* and *S100A12* ($P < .001$ vs baseline and $P < .05$ vs placebo; Figs 2-4 and see Fig E4). Expression of several genes decreased from baseline in nonlesional skin by week 16, including *LCN2*, *PI3*, *CCR1*, *S100A9*, *ITGAX*, *CD1b*, *CCL17*, *CCL22*, *CCL18*, *MMP12*, and *CCL26*; Fig 2). No significant changes from baseline with dupilumab were observed in mRNA expression of *IL4*, *IL5*, *IL1B*, *FOXP3*, *IL23p40*, or *CCL20*. *IL23p19* expression was significantly reduced with dupilumab (vs placebo) at week 4 ($P < .05$), but this result was not replicated at week 16 (Fig 4 and see Fig E4).

Reversal of epidermal responses with dupilumab

Compared with placebo, dupilumab significantly modulated genes related to epidermal pathology in patients with AD, including reduced epidermal proliferation measures (*MKi67*, *K16*, *IL24*, and *IL26*) and increased lipid metabolism and barrier junction genes (*ELOVL3*, *FAR2*, claudin 8 *[CLDN8]*, *CLDN23*, and aquaporin 9 *[AQPN9]*), which often are downregulated in AD lesions.[46,50,54,107] These changes were particularly evident at week 16 (see Table E10).

Changes in epidermal hyperplasia were evaluated in dupilumab- and placebo-treated AD tissues by assessing changes from baseline at weeks 4 and 16 in ET and keratinocyte proliferation markers (K16 protein immunostaining and mRNA expression by using RT-PCR and $Ki67^+$ cellular counts) (Fig 5, *A–F*). Consistent with the transcriptome-profiling results, median (quartile 1-quartile 3) ET of lesional skin at baseline was similar in the dupilumab (128 μm; quartile 1-quartile 3, 99.3-156.0 μm) and placebo (125 μm; quartile 1-quartile 3, 106.0-172.4 μm) groups. Robust decreases from baseline in median lesional ET of −23% (week 4) and −44% (week 16) were observed with dupilumab treatment versus median changes from baseline of −5% (week 4) and +4% (week 16) in the placebo group. The difference in ET reduction between the dupilumab and placebo groups was statistically significant at both weeks 4 and 16 ($P < .01$ at both time points; Fig 5, *A* and *D*). No significant changes were noted in the ET of nonlesional skin (median,



FIG 5. Histologic and barrier changes. **A-C,** Representative histologic images in the placebo and dupilumab groups of hematoxylin and eosin (*H&E*; Fig 5, *A*), K16 (Fig 5, *B*), and FLG (Fig 5, *C*). **D,** Median percentage change in ET at week 4 *(W4)* and week 16 *(W16)* versus baseline in lesional skin (± first and third quartiles). **E,** FCH of K16 mRNA expression in lesional and nonlesional skin at weeks 4 and 16 versus baseline. **F,** Median percentage change in Ki67$^+$ cell counts at weeks 4 and 16 versus baseline in lesional skin (± first and third quartiles). **G,** Log_2 expression/human acidic ribosomal protein *(hARP)* of FLG in lesional skin (at weeks 0, 4, and 16) and nonlesional skin (weeks 0 and 16). Numbers for tissue and time point are shown at top of graph. **H,** Ratio of FLG to K16 expression in lesional skin (at weeks 0, 4, and 16) and nonlesional skin (weeks 0 and 16). Numbers for tissue and time point are shown at top of graph. $+P < .1$, $*P < .05$, $**P < .01$, and $***P < .001$. *Black asterisks*, Significance of comparison between placebo and dupilumab groups; *red asterisks*, significance of comparison versus baseline; *blue asterisks*, significance of comparison between lesional and nonlesional skin.

A

Spearman Correlation vs. % decrease in EASI at Week 16		
Marker	ρ	p-value
% decrease in SCORAD	0.936	0.000
Ki67	0.659	0.005
Histological Score	0.624	0.010
S100A12	0.590	0.013
S100A8	0.581	0.014
FCERI$^+$ cells	0.575	0.020
S100A7	0.536	0.027
Serum CCL18	0.522	0.031
IL-5	0.522	0.032
CD206$^+$ cells	0.513	0.042
IL-31	0.506	0.038
IL-9	0.486	0.048
PI3	0.483	0.049
CCL22	0.470	0.057
IL13	0.458	0.065
IL-10	0.403	0.109
Epidermal Thickness	0.402	0.123
CD1a$^+$ cells	0.381	0.145
IL-12/23p40	0.366	0.149
MMP12	0.347	0.172
CD11c$^+$ cells	0.330	0.212
CCL20	0.300	0.241
Serum CCL17	0.297	0.247
CCL17	0.288	0.262
CXCL1	0.282	0.273
CD3$^+$ cells	0.280	0.294
CCL18	0.278	0.279
K16	0.264	0.307
IFNγ	0.236	0.361
CD1b$^+$ cells	0.236	0.380
FOXP3	0.233	0.368
Serum Periostin	0.227	0.399
CXCL10	0.158	0.544
IL-1β	0.146	0.576
CD1c$^+$ cells	0.141	0.602
CCL26	0.109	0.677
IL-23p19	0.105	0.687
CCL13	0.102	0.698
IL-17A	0.085	0.746
IL-4	-0.030	0.910
Eosin Cationic Protein	-0.079	0.770
Serum IgE	-0.100	0.724
MBP$^+$ cells	-0.150	0.580
FLG	-0.170	0.513
IL-22	-0.208	0.422
CD83$^+$ cells	-0.237	0.377
CD8$^+$ cells	-0.330	0.212
LOR	-0.407	0.105

B

Spearman Correlation vs. Histological Score Improvement at Week 16		
Marker	ρ	p-value
Epidermal Thickness	0.806	0.000
Ki67	0.729	0.002
PI3	0.712	0.003
% decrease in EASI	0.624	0.010
% decrease in SCORAD	0.591	0.018
S100A12	0.578	0.019
IL-31	0.575	0.020
S100A8	0.547	0.031
K16	0.541	0.033
CD11c$^+$ cells	0.532	0.036
IL-12/23p40	0.515	0.041
CCL22	0.479	0.062
CD3$^+$ cells	0.468	0.070
FCERI$^+$ cells	0.456	0.078
CD206$^+$ cells	0.444	0.085
CXCL1	0.438	0.091
CCL17	0.412	0.114
IL-9	0.401	0.124
CCL20	0.382	0.145
CD1b$^+$ cells	0.359	0.172
Serum CCL18	0.359	0.173
IL-23p19	0.329	0.213
Serum CCL17	0.326	0.217
IL-1β	0.303	0.254
CCL26	0.297	0.263
CD1a$^+$ cells	0.294	0.268
S100A7	0.294	0.268
Serum Periostin	0.289	0.295
Serum IgE	0.289	0.295
MMP12	0.218	0.417
FOXP3	0.185	0.491
MBP$^+$ cells	0.183	0.498
IL-13	0.182	0.499
CXCL10	0.124	0.648
CCL18	0.085	0.755
CD1c$^+$ cells	0.074	0.788
IL-10	0.051	0.850
IL-17A	-0.041	0.879
CD8$^+$ cells	-0.044	0.874
CCL13	-0.079	0.771
IL-5	-0.082	0.763
IL-22	-0.160	0.554
IFNγ	-0.162	0.549
CD83$^+$ cells	-0.279	0.294
IL-4	-0.306	0.249
FLG	-0.535	0.035
Eosin Cationic Protein	-0.585	0.019
LOR	-0.688	0.004

C



FIG 6. Clinical and histologic correlations. **A** and **B,** Tables of Spearman correlations of change at week 16 versus baseline in clinical measures, gene expression, and cell counts with percentage decrease in EASI score (Fig 6, *A*) and histologic score (composite *z* score of ET and K16) improvement (Fig 6, *B*). **C,** Heat map of Spearman correlation matrix of measured values at week 16 ordered by unsupervised clustering (and shown by dendrogram).

−8% [−18.3%, 4.8%] in the dupilumab group vs −1% [−14.9%, 43.7%] in the placebo group, $P = .55$; Fig 5, *A*).

Significant reduction in *K16* mRNA expression was observed in lesional skin of dupilumab- versus placebo-treated patients at week 4 ($P < .001$) and week 16 ($P < .05$; Fig 5, *E*). Qualitative assessment of K16 protein immunostaining confirmed the *K16* mRNA results, with no significant change in K16 staining observed in the majority of patients in the placebo group, whereas most dupilumab-treated patients progressively lost the K16 staining through week 16 (the number of K16-positive patients out of the total number of patients treated with dupilumab or placebo at each week is provided; Fig 5, *B*). Significant reductions from baseline in Ki67$^+$ cell counts were also observed in lesional skin of dupilumab-treated patients at week 4 (median, −51% [quartile 1-quartile 3, −83.28% to −16.84%) versus baseline ($P = .0074$), but not at week 16 (−62% [−84.77% to 0.36%]) versus baseline ($P = .2979$; Fig 5, *F* and Table E9). The reductions were not statistically significant in placebo-treated patients at week 4 (+10.7%; −15.13, 87.80) versus baseline ($P = .1434$) and at week 16 (−20.7%; −36.44, 3.17) versus baseline ($P = .1016$). However, the differences were statistically significant with dupilumab versus placebo at week 4 ($P = .0013$) and at week 16 ($P = .0062$; Fig 5, *F* and Table E9).

Increased expression of epidermal terminal differentiation markers with dupilumab treatment

Areas with a lesional phenotype before treatment were characterized by discontinuous and relatively faint expression of filaggrin (FLG; Fig 5, *C*). After 16 weeks of dupilumab treatment, FLG showed stronger and more continuous granular layer expression in samples from areas that had been lesional at baseline (Fig 5, *C*). Baseline mRNA expressions of both *FLG* and loricrin *(LOR)* are reduced in AD lesional versus nonlesional skin,[47,54,72] with significant increases (vs baseline) with dupilumab treatment ($P < .01$) in lesional mRNA expression of both genes to levels similar to that in nonlesional skin at week 16 (Fig 5, *G*, and see Fig E5, *A*, in this article's Online Repository at www.jacionline.org). These increases were even more pronounced when adjusted for the reduction in epidermal hyperplasia (as measured by changes in *K16* mRNA expression; Fig 5, *H*, and see Fig E5, *B*).

Correlation of biomarkers with clinical improvement and reductions in epidermal hyperplasia with dupilumab

We identified markers associated with improvements in clinical, molecular, and histologic measures of AD by



FIG 7. Gene Set Variation Analysis (GSVA). **A,** Improvements in GSVA scores of different gene sets in lesional skin at week 4 *(W4)* and week 16 *(W16)* in placebo and dupilumab groups, with numbers at the bottom of the graph indicating number of genes in each gene set. **B,** Change from baseline *(W0)* of GSVA scores of select gene sets. $+P < .1$, $*P < .05$, $**P < .01$, $***P < .001$. *Black asterisks,* Significance of comparison between placebo and dupilumab; *red asterisks,* significance of comparison versus baseline.

determining correlations of each marker measured in lesional skin using qRT-PCR and immunohistochemistry, and serum biomarkers, with improvements in EASI and SCORAD (clinical disease reversal) scores and reductions in epidermal hyperplasia (histologic disease reversal, as measured based on a combined histologic score of ET and mRNA expression of *K16*; Fig 6). Spearman correlation coefficients of skin and serum biomarkers with percentage change in clinical scores (EASI and SCORAD) and histologic score improvements at week 16 are shown in Fig 6, *A* and *B*, respectively. A heat map showing the relations between biomarkers and with disease scores at week 16 is shown in Fig 6, *C*. SCORAD and EASI disease activity measures were highly correlated with each other and with the histologic score improvement at week 16 (Fig 6, *A* and *B*). Strong, statistically significant, and direct correlations of the hyperplasia-related measures of epidermal proliferation ($Ki67^+$ cells) and histologic score ($P < .01$) were observed with percentage change from baseline in EASI scores at week 16 (Fig 6, *A*). The $Ki67^+$ cell count was also highly correlated with histologic score improvement at week 16 (Fig 6, *B*). Numbers of $Fc\varepsilon RI^+$ and $CD206^+$ DCs and mRNA expression levels of *IL5*, *IL31*, *IL9*, and the IL-22/IL-17–regulated genes (*S100A8*, *S100A12*, *S100A7*, and *PI3*) in the skin were also highly correlated (correlation defined as $\rho \geq 0.2$ and $P < .05$) with the percentage change from baseline in EASI score at week 16 (Fig 6, *A*). Expression of *PI3*, *S100A12*, *S100A8*, and *IL31* was also strongly correlated with histologic

improvement (Fig 6, *B*). The reduction in serum CCL18 expression was highly correlated with the percentage change from baseline in EASI score at week 16 but not with histologic score improvement. $CD11c^+$ cells and *IL-12/23p40* expression were correlated with histologic scores but not the percentage change from baseline in EASI score at week 16 (Fig 6, *A* and *B*). Of note, increases in differentiation markers (*FLG* and *LOR*, $P < .05$) were negatively correlated with histologic scores but not with the percentage change from baseline in EASI scores at week 16 (Fig 6).

Dupilumab induced progressive improvements in inflammatory and barrier responses

We evaluated the effect of dupilumab compared with placebo treatment on expression of previously reported gene signatures[46-48,108] for upregulated and downregulated genes in the AD transcriptome of genes identified in genome-wide association studies of AD.[109] These genes include keratinocyte, T-cell, and DC gene subsets; primary cytokine-treated keratinocytes; epidermal differentiation complex (EDC) genes; and other genes from specific immune pathway subsets or their superenhancers (Fig 7, *A*).[46,107,108,110-119] Only modest improvements were observed in most gene signatures in placebo-treated lesional skin at week 16, with either no improvement or more inflammatory molecular phenotypes at week 4. Dramatic improvements (sometimes exceeding 100%) were observed in dupilumab-treated patients at week 16, with changes already evident at week 4. For example, the gene subsets from untreated keratinocytes and keratinocytes treated with IL-4[46] showed greater than 100% improvement after 4 weeks of treatment with dupilumab compared with placebo. In addition, almost complete improvement toward a more nonlesional molecular phenotype was seen at week 4 in the EDC gene signature.[46,50,55,74] Dupilumab induced significant progressive changes through week 16 that extended beyond the expected type 2 pathway, including suppression of key AD responses in lesional skin (eg, T_H22 and T_H17 pathways) and in cytokine-treated keratinocytes, including innate cytokines.[46,74,107,108,111,120]

Overall, expression signatures of keratinocytes treated with IL-1, TNF-α, or IFN-γ at week 16 were markedly reduced with dupilumab relative to baseline,[46,118] although similar reductions in IFN-γ at week 16 were seen with both dupilumab and placebo. Mean FCH reductions in selected gene signatures in AD lesional and nonlesional skin, including upregulated genes in the MADAD transcriptome; immune genes; and T_H2-, T_H17-, and T_H1-specific genes (Fig 7, *B*) were significantly greater with dupilumab but not placebo.

Dupilumab suppressed circulating markers of type 2 inflammation

Dupilumab (vs placebo) significantly reduced circulating serum concentrations of CCL17, CCL18, and periostin from baseline through week 16 (see Fig E6 and Table E11 in this article's Online Repository at www.jacionline.org). Dupilumab also progressively and significantly reduced total IgE concentrations (see Fig E6 and Table E11), as well as concentrations of multiple allergen-specific IgEs. These included allergen-specific IgEs previously associated with AD and other atopic or allergic type 2 manifestations (eg, staphylococcal enterotoxin A, −61% vs 0%; *Dermatophagoides farinae*, −39% vs 0%; see Table E12 in this article's Online Repository at www.jacionline.org).[90-95] Although concentrations of most specific IgEs were significantly reduced only with dupilumab (except that of sage mugwort *[Artemisia vulgaris]*, $P = .10$), particularly large (>50%) and significant reductions were seen in those of cockroach, staphylococcal enterotoxin A, *Cladosporium* species, Bermuda grass, silver birch, white oak, elm, white ash, Johnson grass, and cat dander (see Table E12). Baseline serum total IgE concentrations were greater than the normal range (119 kU/L) in both groups (see Table E5). The proportion of patients with relatively normal baseline IgE concentrations (<150 kU/L, n = 10) who had positive results for at least 1 of the allergen-specific IgEs tested in the study was 20% (n = 2).

DISCUSSION

The clinical efficacy of dupilumab in patients with moderate-to-severe AD has proved the central role of IL-4 and IL-13 signaling in the pathogenesis of AD. In this study dupilumab targeting helps us better understand the specific pathways that drive AD and mediate its clinical benefit.

This study evaluated both short-term (4 weeks) and longer-term (16 weeks) effects of dupilumab-mediated IL-4Rα blockade on barrier and immune pathomechanisms in the skin of patients with moderate-to-severe AD. Clinical efficacy, safety, and suppression of type 2–related systemic biomarkers were also evaluated. This study demonstrated strong correlations between molecular, histologic, and clinical changes. Most previous studies of broad[121] immune suppressants (including CsA, methotrexate, and NB-UVB) assessed long-term clinical improvements in patients with moderate-to-severe AD but did not perform molecular and cellular correlation analyses in skin biopsy specimens.[4,47,48] Although CsA and NB-UVB have been shown to broadly modulate both immune (including type 2 pathway) and epidermal responses, these treatments have direct effects on keratinocytes and therefore cannot prove the pathogenic role of the type 2 axis in patients with AD.[47,48]

The clinical efficacy and safety of dupilumab monotherapy in this study was consistent with those observed in larger phase 3 AD trials.[24-28] Dupilumab significantly improved AD signs and symptoms, and injection-site reactions and conjunctivitis in this trial were more frequent with dupilumab than with placebo. Aggregated data from dupilumab studies in patients with AD[122] indicate an increased incidence (relative to placebo) of conjunctivitis; however, most cases of conjunctivitis were mild or moderate and resolved or were resolving during study treatment. Of note, a dupilumab-associated increase in conjunctivitis has not been seen in studies of dupilumab in patients with other indications, such as asthma[29,30,33,34] and chronic rhinosinusitis with nasal polyposis.[31]

The parallel, longer-term tissue reversibility of key AD epidermal and immune features with dupilumab treatment was not evaluated. We previously reported significant dose-dependent shifts of the AD transcriptome in patients with AD treated with 4 weeks of dupilumab compared with placebo.[46] Although that small study was the first to associate clinical improvement with suppression of type 2 and other inflammatory markers, it lacked histologic correlates of resolution of the AD-related epidermal pathology. Furthermore, it evaluated only a small number of

patients after 4 weeks of treatment and did not address how specific inhibition of the type 2 pathway affects the AD molecular and cellular profiles with extended treatment.[23,46]

This is the most comprehensive study to establish the ability of dual inhibition of IL-4 and IL-13 signaling to modulate the immune response and epidermal barrier pathomechanisms that typify AD in addition to reversing clinical disease activity. It is also the first study to evaluate tissue responses around the time at which most patients have a maximal clinical response to dupilumab, thus allowing correlation of the extent of disease reversal in skin lesions and circulating markers with clinical responses.[25,26]

Compared with placebo, dupilumab progressively and significantly reduced cellular infiltrates, including $CD3^+$ T cells and various DC subsets, such as $Fc\varepsilon RI^+$ cells, in AD lesions at weeks 4 and/or 16. Dupilumab also induced a strong, rapid, and significant improvement (68.8%) in a robust genomic AD signature, the MADAD transcriptome,[107] after only 4 weeks of treatment, whereas a 10.5% worsening of the AD transcriptome was observed in the placebo group. Progressive modulation of the lesional AD expression profile was achieved at week 16, with an improvement of 110.8% in the dupilumab group but only 55% in placebo-treated patients. This improvement in the placebo group could be explained in part by the much higher dropout rate caused by lack of efficacy in this group. Placebo-treated patients who did not experience relief or even experienced disease exacerbation might have been more likely to drop out of the trial after week 4 but before reaching the 16-week time point. Therefore the placebo group patients remaining at week 16 perhaps represent those with particularly favorable responses to placebo. At week 16, we observed a reversal of the lesional AD phenotype to a level beyond even that of nonlesional skin, and we observed a large shift toward the nonlesional phenotype as early as week 4.

The ability of targeted IL-4Rα blockade with dupilumab to revert the AD skin transcriptome toward that of nonlesional skin is at least comparable with that achievable with a maximal dose of CsA, a broad T- and B-cell immune suppressant[123-126] that is not approved for AD in the United States and use of which is limited because of toxicity.

Blocking IL-4Rα signaling with dupilumab progressively reversed the characteristic epidermal hyperplasia of AD lesions[1,7,55] after 4 and 16 weeks of treatment, as indicated by significant reductions in ET, $Ki67^+$ cells, and K16 protein and gene expression. In parallel, we observed significant increases in mRNA expression of terminal differentiation markers known to be downregulated in patients with AD, including *FLG* and *LOR*, and this was particularly evident after accounting for the concurrent decrease in epidermal proliferation (relative to K16 expression). These increases were coupled with protein localization of FLG that was more homogeneous than the faint and discontinuous staining observed at baseline. These results provide clinical evidence to support the hypothesis from *in vitro* and mouse experiments that IL-4 and IL-13 directly impair the skin barrier and suppress expression of *FLG*, *LOR*, and other EDC and lipid genes.[70-73] Dupilumab treatment significantly increased expression of genes related to lipid metabolism (*ELOVL3* and *FAR2*) and tight junction genes (claudins), genes previously found to be downregulated in AD lesions and also suppressed *in vitro* by type 2 cytokines.[46,50,54,107,127,128] These results confirm previous analyses that showed a negative correlation between type 2 cytokine levels and lipid measures in patients with AD[107] and demonstrate the role of IL-4 and IL-13 in skin barrier dysfunction in patients with AD.

Dupilumab reversed key immune and barrier mechanisms dysregulated in AD skin, with effects extending beyond those expected from dual inhibition of IL-4 and IL-13 signaling, suggesting that chronic type 2 inflammation has secondary effects on other immune axes. Dupilumab potently inhibited type 2 pathway genes as early as week 4, with progressive reductions at week 16 (eg, *IL13*, *CCL17*, *CCL18*, and *CCL26*) and no comparable reductions in the placebo group. *DPP4*, an IL-13–regulated gene being explored as a potential predictive marker for IL-13–specific inhibition in patients with AD, was also downregulated at week 16. Aside from suppression of type 2 genes regulated by IL-4 and/or IL-13 signaling, as expected, dupilumab also significantly downregulated mRNA expression of inflammatory proteases (*MMP12* and *SERPINB4*), T-cell activation (*ICOS* and *CCR7*), and T_H22 and T_H17 pathway genes (eg, *IL17A*, *IL22*, and *S100As*) after 4 and 16 weeks of treatment. Suppression of the T_H17/T_H22 axes correlated with clinical improvements and resolution of epidermal hyperplasia.

Although dupilumab's effects have proved that the type 2 pathway is central to AD pathogenesis, previous studies have shown that the T_H22 and T_H17 pathways can also play contributory roles in the AD phenotype and its epidermal pathology.[1,3-5,7,20,51,53,129,130] However, consistent robust efficacy in patients with AD has been achieved only with dupilumab; inconclusive or less impressive results were obtained with anti–IL-17/IL-23 and anti–IL-22/ILV-094 approaches, suggesting that these axes are not central pathogenic drivers relative to the type 2 axis.[44,45] Future studies with specific IL-22, IL-17, and IL-23 antagonists should determine whether cytokines other than the type 2 IL-4 and IL-13 cytokines have a direct role in AD or are secondary inflammatory effects of chronic type 2 activation.

IL-22 has been linked to epidermal hyperplasia in patients with AD and to inhibition of keratinocyte terminal differentiation[120,131-136] and induction of the S100As,[120,136] processes that further induce hyperplasia.[135,136] IL-22 has also been implicated in expression of antimicrobial peptides and in reduction of *S aureus* colonization.[137]

IL-17 strongly induces antimicrobial peptides, such as β-defensins, cathelicidin, and S100A8.[120,134] In addition to IL-4, IL-17 can further inhibit some barrier measures that are downregulated in patients with AD, including FLG, LOR, and tight junctions[138,139]; it was recently implicated in epidermal proliferation.[140] IL-17 is also thought to play a role in host defense against *S aureus*, which in turn upregulates IL-17.[141,142] Reversal of histologic hyperplasia and/or improvement in AD disease activity with dupilumab treatment was significantly associated not only with reductions in expression of the *S100A7*, *S100A8*, and *S100A12* genes, which have been shown to be induced by IL-17/IL-22,[120] but also with suppression of type $2/T_H2$ measures in the skin (IL-31) and serum (CCL18/PARC). The significant negative correlation between the reduction in epidermal hyperplasia and increases in expression of the terminal differentiation genes *LOR* and *FLG* demonstrates an improvement in skin barrier integrity. Although the reduction in expression of T_H17/T_H22-related genes with IL-4/IL-13 inhibition is not entirely understood, they might result in part from suppression of IL-4/IL-13–mediated induction of DC differentiation[143,144] and might reflect wider networks of inhibition resulting from expression of IL-4Rα on a variety of cells in skin (eg, keratinocytes, DCs, T cells, eosinophils, and mast cells). Data from a study in flaky-tail mice support the existence of IL-4/IL-17 coregulatory networks.[145]

Although the type 2/T_H2 axis is common to all patient populations, various AD phenotypes, such as intrinsic, Asian, and especially pediatric AD, exhibit greater expression of T_H22 and T_H17 cytokines.[1,3,7,130,146-148] Dupilumab appears to have similar efficacy in pediatric and Japanese patients, thus supporting the notion that these other inflammatory pathways are secondary to type 2 inflammation.[149-152]

This study defined robust, progressive, tissue-transcriptional signatures of therapeutic response to dupilumab that could serve as a point of reference for future therapeutic studies across a variety of AD patient populations. It defines a set of skin and circulating biomarkers that correlate with dupilumab-mediated clinical improvements in AD across the atopic or "allergic" spectrum and/or epidermal hyperplasia. Many of these measures are key pathogenic elements of AD and have been linked to successful treatment responses with broad immune-targeting agents, such as CsA and even NB-UVB, in patients with AD.[11,47,48] These measures include significant associations between clinical improvement and type 2/T_H2 markers (eg, IL-13, CCL18, CCL17, CCL26) in the skin and circulation (CCL18, CCL17, and IgE), as well as T_H17/T_H22 pathway–related genes (eg, *S100As*, *CXCL1*, and *PI3*). Changes in markers of epidermal hyperplasia (ET, K16, Ki67, and histological score) and general inflammation (eg, MMP12) were also significantly associated with clinical improvement.

An additional exploratory analysis, which was not previously reported in the longer-term dupilumab studies, was to evaluate the effects of dupilumab on atopic or allergic and type 2 serum biomarkers. Circulating type 2 chemokines have been implicated as biomarkers of AD severity at baseline or as markers of treatment response, and they include CCL17, CCL18, ECP, and periostin.[11,89,153-158] CCL17 and CCL18 are chemokines that attract and activate inflammatory cells expressing CCR4 and CCR8 receptors, whereas the extracellular matrix protein periostin amplifies keratinocyte responses. In our study dupilumab significantly suppressed serum levels of all of these biomarkers, as well as total and allergen-specific IgE concentrations. Although serum total and allergen-specific IgE concentrations were previously associated with greater severity of AD and other type 2 atopic/allergic diseases,[90-95] broad-based treatments have largely failed to cause downregulation of IgE.[47,96-98] Further studies are needed to evaluate the clinical effect on other atopic comorbidities of the dupilumab-induced modulation of circulatory type 2 biomarkers in our study.

Limitations of the current study include the fact that the dose and regimen investigated are different from the approved dose (300 mg every 2 weeks) and the regimens used in the larger phase 3 AD trials (300 mg weekly and 300 mg every 2 weeks),[25-28] as well as the fact that analyses were conducted only to week 16.

Overall, these data further confirm AD as a type 2–driven disease in which IL-4 and IL-13 have a central role. In addition, our results suggest that IL-4/IL-13 signaling contributes to regulation of the IL-17 and IL-22 cytokine networks in patients with AD, given the significant modulation of these pathways that results from IL-4Rα inhibition. These data demonstrate that inhibition of IL-4Rα, which results in dual inhibition of IL-4/IL-13 signaling, can effectively suppress key pathogenic processes in patients with AD, thus supporting the notion that cytokines induce and perpetuate the epidermal alterations in patients with AD.[2,3,68-70,73,120,129,132,133,136] In parallel with increased cytokine activation in skin lesions before treatment,[8-11,49] patients with severe AD have robust systemic cytokine induction, as reflected by the broad abnormalities already observed at the nonlesional skin level.[11,54] Dupilumab significantly improves immune activation in both the skin and blood compartments in parallel with reversal of the pathologic epidermal responses and clinical disease activity. Future studies should also address interactions between the skin microbiome and resolution of clinical disease and tissue inflammation in patients with moderate-to-severe AD.

We thank the patients who participated in the AD-1307 EXPLORE study, as well as Elizabeth Bucknam, Jacqueline Kuritzky, Robert Phillips, Sara Hamon, Colby Burk, and Linda Williams from Regeneron Pharmaceuticals and Dianne Barry from Sanofi Genzyme for their contributions. Editorial assistance was provided by Jamie Lim, PhD, of Excerpta Medica.

Key messages

- **Targeted dual inhibition of IL-4 and IL-13 signaling through anti–IL-4Rα blockade with dupilumab rapidly and progressively suppressed cellular and molecular cutaneous markers of inflammation from week 4 through week 16 and reversed associated epidermal abnormalities while improving disease severity scores and symptoms in patients with moderate-to-severe AD.**
- **Dupilumab significantly suppressed systemic type 2 inflammatory biomarkers in serum, including the type 2–driven chemokines CCL17 and CCL18, periostin, and total and allergen-specific IgEs.**
- **These data further confirm AD as a type 2–driven disease in which IL-4 and IL-13 play a central role in sustaining systemic and cutaneous type 2–driven inflammation and epidermal alterations.**

REFERENCES

1. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2014;73:311-8.
2. Guttman-Yassky E, Dhingra N, Leung DY. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013;13:549-61.
3. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-79.
4. Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2017;21:31-9.
5. Hoffjan S, Stemmler S. Unravelling the complex genetic background of atopic dermatitis: from genetic association results towards novel therapeutic strategies. Arch Dermatol Res 2015;307:659-70.
6. Hanifin JM, Reed ML. Eczema Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis 2007;18:82-91.
7. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015;135:324-36.
8. Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Peng X, Kunjravia N, et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 2016;137:118-29.
9. Czarnowicki T, Malajian D, Shemer A, Fuentes-Duculan J, Gonzalez J, Suárez-Fariñas, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis [letter]. J Allergy Clin Immunol 2015;136:208-11.
10. Esaki H, Czarnowicki T, Gonzalez J, Oliva M, Talasila S, Haugh I, et al. Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development [letter]. J Allergy Clin Immunol 2016;138:1473-7.

11. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 2017;137:603-13.
12. Hjuler KF, Böttcher M, Vestergaard C, Deleuran M, Raaby L, Bøtker HE, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am J Med 2015;128:1325-34.e2.
13. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy 2015;70:1300-8.
14. Silverberg JI, Silverberg NB, Lee-Wong M. Association between atopic dermatitis and obesity in adulthood. Br J Dermatol 2012;166:498-504.
15. Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol 2015;72:606-16.e4.
16. Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017;137:26-30.
17. Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr 2016;169:284-90.e5.
18. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin 2016;32:1645-51.
19. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016;74:491-8.
20. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 2010;125:16-29, e1-11.
21. MacDonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014;111:5147-52.
22. Murphy AJ, MacDonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014;111:5153-8.
23. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9.
24. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016;75:506-15.
25. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52.
26. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335-48.
27. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-303.
28. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018;178:1083-101.
29. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66.
30. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44.
31. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-79.
32. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized double-blind placebo-controlled phase 2 trial. Presented at: World Congress of Gastroenterology at ACG2017; October 13-18, 2017; Orlando, FL.
33. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475-85.
34. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486-96.
35. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017;376:826-35.
36. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Birrell C, Kell C, et al. A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). Poster presented at: 75th Annual Meeting of the American Academy of Dermatology; March 3-7, 2017; Orlando, FL.
37. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized placebo-controlled phase 2, trial (TREBLE). J Am Acad Dermatol 2018;78:863-71.e11.
38. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013;162:89-93.
39. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of AD and its reversibility with broad spectrum and targeted therapies. J Allergy Clin Immunol 2017;139(suppl 4):S65-76.
40. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-8.
41. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-40.
42. Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006;141:290-4.
43. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6.
44. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 2017;26:28-35.
45. Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018;78:872-81.e6.
46. Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014;134:1293-300.
47. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014;133:1626-34.
48. Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128:583-93, e1-4.
49. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol 2017;137:18-25.
50. Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, et al. Identification of novel immune and barrier genes in atopic dermatitis by laser capture microdissection. J Allergy Clin Immunol 2015;135:153-63.
51. Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of T_H2/T_H22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-54.
52. Suárez-Fariñas M, Ungar B, Correa da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 2015;135:1218-27.

53. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-22 producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T_H17 T cells. J Allergy Clin Immunol 2009;123:1244-52.e2.
54. Suárez-Fariñas M, Tintle S, Shemer A, Chiricozzi A, Nograles KE, Cardinale I, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011;127:954-64, e1-4.
55. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009; 124:1235-1244, e58.
56. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007;157: 1103-15.
57. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127:1420-32.
58. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
59. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10, e1-395.
60. Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL-23/type 17 T cell autoimmune axis. Annu Rev Med 2017;68:255-69.
61. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130:145-154, e9.
62. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016;375:345-56.
63. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136-44.
64. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015;373:1318-28.
65. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015;136: 116-24.
66. Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, et al. A3921147 Study Investigators. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol 2016;137:1079-90.
67. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013;34:174-81.
68. Leung DY. Clinical implications of new mechanistic insights into atopic dermatitis. Curr Opin Pediatr 2016;28:456-62.
69. Novak N, Leung DY. Advances in atopic dermatitis. Curr Opin Immunol 2011;23: 778-83.
70. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:332-7.
71. Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 2008;128:2248-58.
72. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124:R7-12.
73. Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol 2014;134:1941-50.
74. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7.
75. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-9.
76. Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY. The constitutive capacity of human keratinocytes to kill *Staphylococcus aureus* is dependent on β-defensin 3. J Invest Dermatol 2007;127:2368-80.
77. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
78. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of *Staphylococcus aureus* to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001;116:658-63.
79. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2:pii 110.
80. Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine 2013; 61:419-25.
81. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy 2002;1:263-9.
82. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-41.
83. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005;60: 685-8.
84. Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin North Am 2017;37:51-61.
85. Gebhardt M, Wenzel HC, Hipler UC, Herrmann D, Wollina U. Monitoring of serologic immune parameters in inflammatory skin diseases. Allergy 1997;52: 1087-94.
86. Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M, et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br J Dermatol 2014;171:283-91.
87. Hon KL, Ching GK, Ng PC, Leung TF. Exploring CCL18, eczema severity and atopy. Pediatr Allergy Immunol 2011;22:704-7.
88. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113:334-40.
89. Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen H-C, Gonzalez J, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep 2017;7:8707.
90. Mittermann I, Wikberg G, Johansson C, Lupinek C, Lundeberg L, Crameri R, et al. IgE sensitization profiles differ between adult patients with severe and moderate atopic dermatitis. PLoS One 2016;11:e0156077.
91. Dzoro S, Mittermann I, Resch-Marat Y, Vrtala S, Nehr M, Hirschl AM, et al. House dust mites as potential carriers for IgE sensitization to bacterial antigens. Allergy 2017;73:115-24.
92. Čelakovská J, Ettlerová K, Ettler K, Vaněčková J, Bukač J. Sensitization to aeroallergens in atopic dermatitis patients: association with concomitant allergic diseases. J Eur Acad Dermatol Venereol 2015;29:1500-5.
93. Huss K, Adkinson NF Jr, Eggleston PA, Dawson C, Van Natta ML, Hamilton RG. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol 2001;107:48-54.
94. Bonyadi MR, Hassanzadeh D, Seyfizadeh N, Borzoueisileh S. Assessment of allergen-specific IgE by immunoblotting method in atopic dermatitis. Eur Ann Allergy Clin Immunol 2017;49:213-9.
95. Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. J Intern Med 2012;272:133-43.
96. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160:652-8.
97. Lucae S, Schmid-Grendelmeier P, Wüthrich B, Kraft D, Valenta R, Linhart B. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment. Allergy 2016;71:115-8.
98. Hijnen DJ, Knol E, Bruijnzeel-Koomen C, de Bruin-Weller M. Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis 2007;18:163-5.
99. Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy 2015;7:1043-58.

100. Brunner PM, Khattri S, Garcet S, Finney R, Oliva M, Dutt R, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2016;138:169-78.
101. Ungar B, Correa da Rosa J, Shemer A, Czarnowicki T, Estrada YD, Fuentes-Duculan J, et al. Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. Exp Dermatol 2017;26:272-5.
102. Kattan JD, Sicherer SH, Sampson HA. Clinical reactivity to hazelnut may be better identified by component testing than traditional testing methods. J Allergy Clin Immunol Pract 2014;2:633-4.
103. Suárez-Fariñas M, Pelligrino M, Wittkowski KM, Magnasco MO. Harshlight: a "corrective make-up" program for microarray chips. BMC Bioinformatics 2005;6:294.
104. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004;99:909-17.
105. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
106. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013;14:7.
107. Ewald DA, Malajian D, Krueger JG, Workman CT, Wang T, Tian S, et al. Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Med Genomics 2015;8:60.
108. Dhingra N, Shemer A, Correa da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol 2014;134:362-72.
109. Baurecht H, Hotze M, Brand S, Buning C, Cormican P, Corvin A, et al. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet 2015;96:104-20.
110. Suárez-Fariñas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol 2015;136:1277-87.
111. Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SC, Erdos MR, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 2015;520:558-62.
112. Ortiz RA, Barnes KC. Genetics of allergic diseases. Immunol Allergy Clin North Am 2015;35:19-44.
113. Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol 2016;12:52.
114. Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol 2014;41:213-20.
115. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet 2015;47:1449-56.
116. Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 2007;157:441-9.
117. de Guzman Strong C, Conlan S, Deming CB, Cheng J, Sears KE, Segre JA. A milieu of regulatory elements in the epidermal differentiation complex syntenic block: implications for atopic dermatitis and psoriasis. Hum Mol Genet 2010;19:1453-60.
118. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87.
119. Swindell WR, Johnston A, Xing X, Voorhees JJ, Elder JT, Gudjonsson JE. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One 2013;8:e79253.
120. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102.
121. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69:46-55.
122. Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis [response to letter]. N Engl J Med 2017;376:1090-1.
123. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 2012;7:e31465.
124. Haider AS, Lowes MA, Suárez-Fariñas M, Zaba LC, Cardinale I, Khatcherian A, et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-20.
125. Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009;64:1588-96.
126. Tajima K, Amakawa R, Ito T, Miyaji M, Takebayashi M, Fukuhara S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003;108:321-8.
127. De Benedetto A, Slifka MK, Rafaels NM, Kuo IH, Georas SN, Boguniewicz M, et al. Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol 2011;128:242-6.
128. Kuo IH, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 2013;131:266-78.
129. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008;128:2625-30.
130. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 2015;136:1254-64.
131. Nograles KE, Suárez-Fariñas M, Shemer A, Fuentes-Duculan J, Chiricozzi A, Cardinale I, et al. Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. J Allergy Clin Immunol 2010;125:744-6.
132. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009;39:3570-81.
133. Donetti E, Cornaghi L, Arnaboldi F, Landoni F, Romagnoli P, Mastroianni N, et al. Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. Exp Cell Res 2016;345:247-54.
134. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40.
135. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci 2013;72:3-8.
136. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695-702.
137. Mulcahy ME, Leech JM, Renauld JC, Mills KH, McLoughlin RM. Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa. Mucosal Immunol 2016;9:1429-41.
138. Rabeony H, Petit-Paris I, Garnier J, Barrault C, Pedretti N, Guilloteau K, et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1α, TNFα and oncostatin M. PLoS One 2014;9:e101937.
139. Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One 2016;11:e0161759.
140. Ma WY, Jia K, Zhang Y. IL-17 promotes keratinocyte proliferation via the down-regulation of C/EBPα. Exp Ther Med 2016;11:631-6.
141. Björkander S, Hell L, Johansson MA, Forsberg MM, Lasaviciute G, Roos S, et al. *Staphylococcus aureus*-derived factors induce IL-10, IFN-γ and IL-17A-expressing $FOXP3^+$ $CD161^+$ T-helper cells in a partly monocyte-dependent manner. Sci Rep 2016;6:22083.
142. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17 is essential for host defense against cutaneous *Staphylococcus aureus* infection in mice. J Clin Invest 2010;120:1762-73.
143. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-61.
144. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013;38:336-48.
145. Nakajima S, Kitoh A, Egawa G, Natsuaki Y, Nakamizo S, Moniaga CS, et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol 2014;134:2122-30.
146. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 2013;132:361-70.

147. Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is T_H2 but also T_H17 polarized in skin. J Allergy Clin Immunol 2016;138:1639-51.
148. Czarnowicki T, Esaki H, Gonzalez J, Malajian D, Shemer A, Noda S, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 2015;136:941-51.
149. Igarashi A, Kawashima M, Etoh T, Ohtsuki M, Okuizumi K, Arima K, et al. A multinational phase 2b clinical trial of dupilumab in adults with atopic dermatitis [abstract]. Presented at: 115th Annual Meeting of the Japanese Dermatological Association; June 3-5, 2016; Kyoto, Japan.
150. Kataoka Y, Kabashima K, Hide M, Katoh N, Saeki H, Kawashima M, et al. A multinational phase 3 trial of dupilumab in adults with moderate-to-severe atopic dermatitis (SOLO 1): a Japanese subanalysis. Presented at: 117th Annual Meeting of the Japanese Dermatological Association; May 31-June 3, 2018; Hiroshima, Japan.
151. Etoh T, Imafuku S, Igarashi A, Fujita H, Arima K, Zhu X, et al. A multinational phase 3 clinical trial of dupilumab in adults with atopic dermatitis (CHRONOS): a Japanese subanalysis. Presented at: 117th Annual Meeting of the Japanese Dermatological Association; May 31-June 3, 2018; Hiroshima, Japan.
152. Cork MJ, Thaçi D, DiCioccio AT, Davis JD, Zhang Q, Ardeleanu M, et al. Pharmacokinetics, safety and efficacy of dupilumab in a pediatric population with moderate-to-severe atopic dermatitis: results from an open-label phase 2a trial. J Am Acad Dermatol 2017;76(suppl 1):AB 5279.
153. Sung M, Lee KS, Ha EG, Lee SJ, Kim MA, Lee SW, et al. An association of periostin levels with the severity and chronicity of atopic dermatitis in children. Pediatr Allergy Immunol 2017;28:543-50.
154. Kwon YS, Oh SH, Wu WH, Bae BG, Lee HJ, Lee MG, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. Exp Dermatol 2010;19:246-51.
155. Fukuie T, Hirakawa S, Narita M, Nomura I, Matsumoto K, Tokura Y, et al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study. J Dermatol 2016;43:1283-92.
156. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol 2015;15:453-60.
157. Brunner PM, Emerson RO, Tipton C, Garcet S, Khattri S, Coats I, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy 2017;72:2017-25.
158. Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Csomor E, et al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. J Allergy Clin Immunol 2017;140:730-7.

ONLINE REPOSITORY

Supplementary text

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

MATERIALS AND METHODS

Study design

A central randomization scheme was used and provided by an interactive response technology system to the designated study pharmacist or qualified designee. Drug kits were coded, masking the treatment assigned.

The study was conducted in accordance with current FDA regulations and guidelines, International Conference on Harmonization guidelines on Good Clinical Practice, the ethical principles of the Declaration of Helsinki, as well as all other applicable national and local laws and regulations. All study documents and procedures were approved by the appropriate institutional review boards (IRBs) and ethics committees at each study site. The study was initiated (first patient, first visit) on November 15, 2013, and concluded with the last patient's last visit on January 30, 2015.

Patients

Patients were required to apply stable doses of a topical emollient (moisturizer) twice daily for ≥7 days before the baseline visit and ≥7 days after the baseline visit (day −7 to day 8). After day 8, continued use of emollients was optional.

Statistical analyses

The safety analysis set included all randomized patients who received study drug; patients were analyzed as treated. The full analysis set included all patients randomized into this study who received ≥1 dose of study drug; patients were analyzed as randomized, and analyses were performed using analysis of covariance, with values collected after treatment rescue set to missing. Secondary categorical variables were analyzed using a Cochran-Mantel-Haenszel test stratified by randomization strata defined as moderate if the Investigator's Global Assessment (IGA) score = 3 and severe if IGA score = 4. Missing values for primary and secondary

continuous variables were imputed using the last observation carried forward method while data were set to missing after rescue medication.

Supplementary figure legends

FIG E1. CONSORT flow diagram of study patients.

FIG E2. Clinical outcomes. Least squares (LS) mean percent change ± standard error (SE) in Eczema Area and Severity Index (EASI) score from baseline to week 16 (**A**). Proportion of patients achieving reductions of 50%, 75%, and 90% from baseline in EASI score (EASI-50, EASI-75, and EASI-90, respectively) at week 16 (**B**). Representative clinical images from a patient before and after receiving dupilumab treatment (**C**). LS mean percent change ± SE in peak pruritus numerical rating scale (NRS) score from baseline at week 16 (**D**). *$P < 0.05$; **$P < 0.01$; ***$P \leq 0.001$.

FIG E3. Representative histological images in placebo and dupilumab groups of $CD3^+$ T-cells (**A**), $CD11c^+$ dendritic cells (**B**), $C206^+$ dendritic cells (**C**), and MBP^+ eosinophils (**D**).

FIG E4. Fold changes (FCH) of inflammatory markers in lesional skin at week 4 (W4) and week 16 (W16) and in nonlesional skin at w16, vs baseline (W0). *Black stars*: significance of comparison between placebo and dupilumab groups, *red stars*: significance of comparison vs baseline. +$P < 0.1$; *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$.

FIG E5. Line graphs of mRNA expressions of loricrin (LOR) (**A**) and LOR to keratin 16 (K16) ratio (**B**) at baseline (W0), week 4 (W4), and week 16 (W16) shown (n for each time point included). *Black stars*: significance of comparison between placebo and dupilumab groups, *red stars*: significance of comparison vs baseline, *blue stars*: significance of comparison of lesional and nonlesional expression levels at same time point. +$P < 0.1$; *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$.

FIG E6. Mean percent change in serum levels of total IgE (**A**), CCL17/TARC (**B**), CCL18/PARC (**C**), and periostin (**D**) in dupilumab and placebo groups from baseline to week 16. N for each group at all time points indicated in table below each graph.


Screened: N = 66
Excluded from study (n = 12)
Reason:
• Not meeting inclusion criteria (5)
• Withdrew consent (2)
• Met exclusion criteria (5)
Randomized: N = 54
Allocation
Placebo
qw
n = 27
Dupilumab
200 mg qw
n = 27
Discontinued the study
(n = 2)
Reason:
Withdrawal by patient (2)
Discontinued the study
(n = 1)
Reason:
AE (1)
Completed study
to Week 16
n = 25
Completed study
to Week 16
n = 26
Follow-up
Discontinued the study
(n = 14)
Reason:
Lack of efficacy (8)
Physician decision (2)
Withdrawal by patient (2)
AE (2)
Discontinued the study
(n = 10)
Reason:
Lack of efficacy (1)
Physician decision (3)
Withdrawal by patient (3)
AE (2)
Pregnancy (1)
Completed study
to Week 32
n = 13
Completed study
to Week 32
n = 17


A
Percent Change from Baseline to Week 16 in EASI Score
Placebo
Dupilumab 200 mg qw
LS mean % change from baseline ± SE
20
10
0
−10
−20
−30
−40
−50
−60
−70
−80
−90
***
0
2
4
6
8
10
12
14
16
Week


C
Baseline (WD)
Week 4
Week 16
Placebo
Dupilumab 200 mg qw


B
% of patients ± SE
80
60
40
20
0
***
***
**
22.2%
77.8%
14.8%
66.7%
0%
33.3%
Placebo
Dupilumab
EASI-50
EASI-75
EASI-90


D
Percent Change from Baseline at Week 16 in Peak Pruritus NRS Score
LS mean % change from baseline ± SE
0
−10
−20
−30
−40
−50
−60
−6.33%
−51.53%
**
Placebo
Dupilumab


Lesional
Non-Lesional
Baseline
Week 4
Week 16
Baseline
Week 16
A
Placebo
CD3
Dupilumab
CD3
B
Placebo
CD11c
Dupilumab
CD11c
C
Placebo
CD206
Dupilumab
CD206
D
Placebo
MBP
Dupilumab
MBP


Innate Immunity
IL-1β
Th2
IL-4
IL-5
Th17
IL-12/23p40
IL-23p19
CCL20
Th17/Th22
S100A8
Negative Regulator
FOXp3
FCH (vs. baseline)
W4
W16
W16
Lesional
Placebo
Dupilumab
Non-lesional
Placebo
Dupilumab

Lesional
- Placebo
- Dupilumab

Non-lesional
- Placebo
- Dupilumab



Week	Screening	0	2	4	6	8	10	12	14	16
PBO (n = 27)	27	27	0	21	0	15	0	0	0	13
200 mg qw (n = 27)	27	27	0	24	0	24	0	0	0	21



Week	Screening	0	1	2	3	4	6	8	10	12	14	15	16
PBO (n = 27)	27	27	26	25	26	22	16	14	15	14	12	13	12
200 mg qw (n = 27)	27	27	27	26	25	24	24	24	24	23	23	22	21



Week	Screening	0	1	2	3	4	6	8	10	12	14	15	16
PBO (n = 27)	27	27	26	25	25	22	16	14	15	14	12	13	12
DPL (n = 27)	27	27	27	26	24	24	24	24	24	23	23	22	21



Week	Screening	0	1	2	3	4	6	8	10	12	14	15	16
PBO (n = 27)	26	27	26	25	26	21	16	14	13	13	11	13	12
DPL (n = 27)	27	27	27	26	24	24	24	24	24	23	22	22	20

ONLINE REPOSITORY

Supplementary tables

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

TABLE E1. Study endpoints

Endpoint	Scale[a]
Change in EASI score from baseline to week 16, %	0–72; MCID = 6.6[1,2]
Proportion of patients with ≥ 50%, ≥ 75%, or ≥ 90% EASI improvement at week 16	
Proportion of patients with an IGA score of 0 or 1 at week 16	0–4
Reduction in IGA of ≥2 at week 16	
Change in peak weekly pruritus NRS scale from baseline to week 16, %	0–10; MCID = improvement of ≥ 3 or ≥ 4[‡3]
SCORing Atopic Dermatitis (SCORAD) from baseline to week 16	0–103; MCID = 8.7[2]
Proportion of patients with ≥ 50%, ≥ 75%, or ≥ 90% SCORAD improvement at week 16	
Mean change from baseline to week 16 in POEM score	7 items; 0–28; MCID = 3.4[2]
Mean change from baseline to week 16 in GISS total score and individual components	0–12 (cumulative score)

EASI, Eczema Area and Severity Index; GISS, Global Individual Signs Score; MCID, minimum clinically important difference; NRS, numerical rating scale; POEM, Patient-Oriented Eczema Measure.

[a] Higher scores indicate greater severity.

References

1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11–8.
2. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012;67:99–106.
3. Simpson E, Beck L, Gadkari A, et al. Defining a responder on the peak pruritus numerical rating scale (NRS) in patients with moderate-to-severe atopic dermatitis: detailed analysis from randomized trials of dupilumab. American Academy of Dermatology, 75th Annual Meeting, March 3–7, 2017; Orlando, FL, USA: Abstr 4789.

TABLE E2. Adverse events reported during the study period (from baseline to week 32)

Overview of TEAEs	**Placebo qw n = 27**	**Dupilumab 200 mg qw n = 27**
Patients with, n (%)		
≥ 1 TEAE	23 (85.2)	24 (88.9)
Any serious TEAE	3 (11.1)	0
TEAEs resulting in temporary drug withdrawal	1 (3.7)	0
TEAEs resulting in permanent drug withdrawal	4 (14.8)	3 (11.1)
Most commonly reported TEAEs[a]		
Patients with TEAEs, n (%)		
Nasopharyngitis	5 (18.5)	3 (11.1)
Upper respiratory tract infection	4 (14.8)	4 (14.8)
Dermatitis atopic	4 (14.8)	4 (14.8)
Injection-site reactions[b]	1 (3.7)	5 (18.5)
Viral upper respiratory tract infection	2 (7.4)	3 (11.1)
Conjunctivitis[c]	1 (3.7)	3 (11.1)
Herpes viral infections[d]	1 (3.7)	2 (7.4)
Fatigue	1 (3.7)	2 (7.4)
Back pain	2 (7.4)	1 (3.7)
Headache	1 (3.7)	2 (7.4)
Folliculitis	0	2 (7.4)
Post-procedural infection	0	2 (7.4)
Gastroenteritis	0	2 (7.4)
Dermatitis infected	2 (7.4)	0
Contusion	0	2 (7.4)
Presyncope	0	2 (7.4)

HLT, MedDRA High-Level Term; MedDRA, Medical Dictionary for Regulatory Activities; PT, MedDRA Preferred Terms; qw, weekly; TEAEs, treatment-emergent adverse events.

[a] TEAEs reported in >1 patient in any treatment group. These TEAEs are summarized as PT, except for injection-site reactions, conjunctivitis (i.e., conjunctival infections, irritations, and inflammation), and herpes viral infections, where HLT level was used to summarize clusters of similar AEs considered clinically related.

[b] Injection-site reactions (HLT) include injection-site erythema, injection-site reaction, and injection-site bruising (PTs).

[c] Conjunctival infections, irritations, and inflammation ('conjunctivitis' in table) (HLT) include conjunctivitis allergic, atopic keratoconjunctivitis, conjunctivitis irritation, and conjunctivitis (PTs).

[d] Herpes viral infections (HLT) include eczema herpeticum, herpes simplex, and herpes zoster (PTs).

TABLE E3. Immunohistochemistry antibodies

Antigen	Manufacturer	Clone[a]	Isotype	Dilution
CD11c	BD Biosciences	B-Iy6	IgG1	1:100
CD1a	Abcam	CD1a007	IgG1	1:25
CD1c	Miltenyi Biotec	AD5-8E7	IgG2a	1:100
CD206	Genetex	15-2	IgG1	1:100
CD3	BD Biosciences	SK7	IgG1	1:100
FceR1	Thermo Scientific	CRA1(AER37)	IgG2b, kappa	1:100
Filaggrin	Acris Antibodies	FLG01	IgG1	1:100
K16	Sigma Aldrich	K8.12	IgG1	1:100
Ki67	Santa Cruz	MIB-1	IgG1	1:100
MBP	Thermo Scientific	BMK13	IgG1	1:15

[a] Antibodies used in this experiment were mouse monoclonal unless stated otherwise.

TABLE E4. qRT-PCR primers and probes

Gene	Assay ID
CCL13	Hs00234646_m1
CCL17	Hs00171074_m1
CCL18	Hs00268113_m1
CCL20	Hs01011368_m1
CCL22	Hs01574247_m1
CCL26	Hs00171146_m1
CXCL1	Hs00236937_m1
CXCL10	Hs01124251_g1
FLG	Hs00856927_m1
FOXp3	Hs01085834_m1
IFNγ	Hs00989291_m1
IL-10	Hs00961622_m1
IL-12/23p40	Hs01011518_m1
IL-13	Hs00174379_m1
IL-17A	Hs00174383_m1
IL-22	Hs01574154_m1
IL-23p19	Hs00900828_g1
IL-31	Hs01098710_m1
IL-4	Hs00174122_m1
IL-5	Hs00174200_m1
IL-9	Hs00914237_m1
K16	Hs00955082_g1
LOR	Hs01894962_s1
MMP12	Hs00899662_m1
PI3	Hs00160066_m1
S100A12	Hs00942835_g1
S100A7	Hs01923188_u1
S100A8	Hs00374264_g1

qRT-PCR, quantitative real-time polymerase chain reaction.

TABLE E5. Baseline patient demographics and clinical characteristics by treatment group (N = 54)

Characteristic	**Placebo qw n = 27**	**Dupilumab 200 mg qw n = 27**	***P* value dupilumab vs placebo**
Age, median (Q1, Q3), years	43 (34, 49)	35 (27, 50)	0.168
Male sex, n (%)	14 (51.9)	16 (59.3)	0.584
Race, n (%)			
White	20 (74.1)	19 (70.4)	
Black or African–American	3 (11.1)	3 (11.1)	0.761
Asian	3 (11.1)	5 (18.5)	
Other	1 (3.7)	0	
Duration of AD, median (Q1, Q3), years	38 (28, 45)	25 (7, 39)	0.051
BSA affected, median (Q1, Q3), %	57 (33, 80)	43 (26, 86)	0.933
EASI score (0–72), median (Q1, Q3)[a]	34 (19, 44)	30 (18, 49)	0.855
IGA score (0–4), n (%)[b]			
3 (moderate)	13 (48.1)	14 (51.9)	0.785
4 (severe)	14 (51.9)	13 (48.1)	
Peak pruritus NRS score (0–10), median (Q1, Q3)[c]	8 (6, 9)	8 (6, 9)	0.626
Total SCORAD score (0–103), median (Q1, Q3)[d]	64 (56, 76)	65 (49, 79)	0.832
Total POEM score (0–28), median (Q1, Q3)[e]	22 (19, 27)	21 (19, 27)	0.865
Total GISS score (0–12), median (Q1, Q3)[f]	9 (8, 11)	8 (7, 10)	0.320
Serum TARC, mean ± SD, pg/mL	11,362 ± 24,674	7,722 ± 13,587	0.506
Serum PARC, mean ± SD, ng/mL	206 ± 188	168 ± 126	0.392
Serum periostin, mean ± SD, ng/mL	146 ± 98	154 ± 117	0.789
Serum total IgE, mean ± SD, IU/mL	5,641 ± 4,706	3,868 ± 4,248	0.152
Serum ECP, mean ± SD, ng/mL	58 ± 85	41 ± 44	0.358
Blood eosinophil count, median (Q1, Q3), 10^9/L	0 (0.3, 0.6)	0 (0.2, 0.8)	0.556
Epidermal thickness, lesional skin, median (Q1, Q3), µm	125 (106, 172)	128 (99, 156)	0.866
Epidermal thickness, nonlesional skin, median (Q1, Q3), µm	59 (47, 68)	73 (64, 83)	0.010

AD, atopic dermatitis; BSA, body surface area; ECP, eosinophil cationic protein; qw, once weekly; POEM, Patient-Oriented Eczema Measure; Q1, lower quartile of interquartile range; Q3, upper quartile of interquartile range; SD, standard deviation.

[a] EASI scores range from 0 to 72 (higher scores indicate greater severity); a change of 6.6 has been estimated as the MCID.

[b] IGA scores range from 0 to 4 (higher scores indicate greater severity); the MCID for IGA has not been determined.

[c] The peak pruritus NRS score is a patient-reported measure that assesses the maximum itch intensity in the previous 24 hours, on a scale ranging from 0 to 10 (higher values indicate worse itching).

[d] SCORAD is a combined score of investigator-reported disease severity and affected BSA with patient-reported symptoms of itch and sleep dysfunction; scores range from 0 to 103 (higher scores indicate greater severity); a change of 8.7 has been estimated as the MCID.

[e] POEM, a composite measure of patient-reported symptoms including the effect of symptoms on sleep, evaluates the frequency of symptoms (including itching) and the effect of AD on sleep on a scale ranging from 0 to 28 (higher scores indicate greater severity); a change of 3.4 has been estimated as the MCID.

[f] GISS is a cumulative score of ratings for individual components of lesions associated with AD (erythema, infiltration or papulation, excoriations, and lichenification); the cumulative score ranges from 0 to 12 (higher scores indicate greater severity); the MCID for GISS has not been determined.

TABLE E6. Number of patients in the biopsy cohort

Group	Placebo	Dupilumab
Nonlesional skin, week 0	20	22
Lesional skin, week 0	25	26
Lesional skin, week 4	20	24
Lesional skin, week 16	11	18
Nonlesional skin, week 16	7	15

TABLE E7. Number of patients available for blood analyses

Blood biomarker	Week	Placebo	Dupilumab 200 mg qw
Total IgE	0	27	27
	4	21	24
	16	13	21
CCL17/TARC	0	27	27
	4	22	24
	16	12	21
CCL18/PARC	0	27	27
	4	22	24
	16	12	21
Periostin	0	27	27
	4	21	24
	16	12	20

IgE, immunoglobulin E; PARC, pulmonary and activation-regulated chemokine; TARC, thymus and activation-regulated chemokine.

TABLE E8. Efficacy outcomes (from baseline to week 16)

Outcome		Placebo qw n = 27	Dupilumab 200 mg qw n = 27	*P* value vs placebo
Primary outcome				
EASI score, LS mean percent	LOCF	−5.8 ± 8.16	−75.2 ± 8.15	< 0.0001
change from baseline to week 16	MMRM	−38.7 ± 6.74	−81.6 ± 4.96	< 0.0001
Secondary outcomes				
IGA score 0 or 1 at week 16, n (%)		0	10 (37.0)	0.0006
Reduction in IGA score of ≥2 at week 16, n (%)		1 (3.7)	14 (51.9)	< 0.0001
Peak pruritus NRS score				
LS mean percent change from baseline to week 16		−6.3 ± 10.01	−51.5 ± 10.20	0.0027
LS mean change from baseline to week 16		−1.2 ± 0.44	−3.6 ± 0.45	0.0002
EASI score, LS mean change from baseline to week 16		−3.7 ± 2.65	−25.2 ± 2.65	< 0.0001
Total SCORAD score				
LS mean percent change from baseline to week 16		−8.2 ± 5.41	−54.8 ± 5.40	< 0.0001
LS mean change from baseline to week 16		−5.1 ± 3.60	−36.4 ± 3.60	< 0.0001
EASI-50[a] at week 16, n (%)		6 (22.2)	21 (77.8)	< 0.0001
EASI-75[a] at week 16, n (%)		4 (14.8)	18 (66.7)	0.0001
EASI-90[a] at week 16, n (%)		0	9 (33.3)	0.0011
SCORAD-50[a] at week 16, n (%)		2 (7.4)	15 (55.6)	0.0002
SCORAD-75[a] at week 16, n (%)		0	3 (11.1)	0.0792
SCORAD-90[a] at week 16, n (%)		0	2 (7.4)	0.1573
Total POEM score				
LS mean percent change from baseline to week 16		−12.1 ± 6.18	−58.3 ± 6.31	< 0.0001
LS mean change from baseline to week 16		−2.6 ± 1.34	−13.1 ± 1.37	< 0.0001
Total GISS, LS mean change from baseline to week 16		−0.5 ± 0.46	−4.2 ± 0.46	< 0.0001
GISS components, LS mean change from baseline to week 16				
Erythema GISS		0.0 0.14	−0.7 ± 0.14	0.0014
Infiltration/papulation GISS		−0.1 ± 0.13	−1.0 ± 0.13	< 0.0001
Excoriation GISS		−0.3 ± 0.14	−1.3 ± 0.14	< 0.0001
Lichenification GISS		−0.1 ± 0.14	−1.2 ± 0.14	< 0.0001

EASI-50/75/90, 50%/75%/90% reduction in EASI score; ECP, eosinophil cationic protein; LOCF, last observation carried forward; LS, least squares; MMRM, Mixed-Effect Model Repeated Measure; SCORAD-50/75/90, 50%/75%/90% reduction in SCORAD score.
Plus-minus (±) values are mean ± SE. Data censored after rescue treatment. All *P* values for secondary endpoints are nominal vs placebo.
[a] Missing = non-responder.

TABLE E9. Immunohistochemistry (IHC)

IHC marker	Study week	Median % change from baseline		Q1: Q3		*P* value (dupilumab vs placebo)	*P* value (vs week 0)	
		Placebo	Dupilumab	Placebo	Dupilumab		Placebo	Dupilumab
CD3	4	−34.7	−22.6	−50.54: 15.51	−52.41: 17.98	0.458	0.7246	0.1342
	16	−6.9	−56.4	−45.49: 13.87	−71.96: −39.60	0.001	0.4648	< 0.0001
CD8	4	1.2	−20.8	−35.71: 128.57	−45.45: 75.00	0.1917	0.3339	0.6946
	16	−20	−17.9	−45.45: 42.11	−68.55: 46.07	0.1496	0.7695	0.4954
CD11c	4	−9.0	−49.9	−30.53: 45.97	−68.71: −21.93	0.0006	0.6747	< 0.0001
	16	−30.1	−77.7	−41.92: 5.73	−80.60: −48.09	0.0013	0.1748	< 0.0001
CD1a	4	24.2	−8.1	−32.56: 56.86	−42.62: 33.33	0.3285	0.2774	0.9273
	16	16.1	−40.7	−33.33: 50.00	−61.53: −26.82	0.0036	0.249	0.0002
CD1b	4	5.9	−57.2	−40.00: 115.00	−80.43: 50.00	0.0991	0.1873	0.0752
	16	−2	−10	−8.00: 12.00	−30.50: −2.00	0.0796	0.9219	0.006
CD1c	4	−13.5	−31.7	−36.46: 24.56	−54.55: 3.23	0.047	0.6023	0.0149
	16	−10.9	−62.0	−39.68: 38.80	−79.79: −33.46	0.0014	0.8984	0.0063
CD83	4	25.4	−30.8	−50.75: 135.64	−50.00: 150.00	0.152	0.1245	0.8878
	16	−17	−10	−58.00: −5.00	−45.50: −55.00	0.6254	0.0537	0.7531
CD206	4	−4.9	−15.0	−27.50: 37.79	−28.51: 10.66	0.0997	0.8538	0.1528
	16	−17.9	−42.3	−37.90: 16.33	−61.16: −7.60	0.0011	0.4648	0.0017
FcεRI	4	−0.5	1.7	−31.14: 27.40	−43.98: 30.56	0.6912	0.9066	0.9866
	16	−11.2	−43.6	−36.44: 33.18	−61.39: −6.67	0.0479	0.9658	0.0386
MBP	4	0	−27.6	−63.72: 100.00	−88.12: 150.00	0.3729	0.5796	0.4958
	16	−75.0	−96.6	−86.36: −3.54	−100.00: −16.67	0.1104	0.0391	0.0188

Ki67	4	10.7	−51.0	−15.13: 87.80	−83.28: −16.84	0.0013	0.1434	0.0074
	16	−20.7	−62.0	−36.44: 3.17	−84.77: 0.36	0.0062	0.1016	0.2979

TABLE E10. Differentially expressed genes and differentially regulated genes with treatment

NOTE: As Table E10 is an excel file, it has been uploaded separately.

77 **TABLE E11.** Serum biomarker responses

Serum marker	Week	Placebo, median percent change from baseline (Q1;Q3)	Dupilumab, median percent change from baseline (Q1;Q3)	*P* value
Total IgE	4	0 (0.0;8.2)	−4 (−20.7;0.0)	0.0009
	16	0 (0.0;11.0)	−54 (−65.8;−23.9)	< 0.0001
CCL17/TARC	4	4 (−22.5;38.0)	−79 (−83.8;−62.6)	< 0.0001
	16	−11 (−61.9;27.5)	−76 (−85.8;−57.0)	0.0002
CCL18/PARC	4	15 (−7.6;41.5)	−63 (−74.6;−49.0)	< 0.0001
	16	−16 (−36.0;41.7)	−68 (−79.4;−48.3)	< 0.0001
Periostin	4	14 (−11.1;38.2)	−31 (−45.1;−12.2)	< 0.0001
	16	6 (−19.8;19.8)	−47 (−61.8;−12.1)	0.0050
ECP	4	−6 (−24.2;52.5)	−8 (−48.5;46.8)	0.5006
	16	−10 (−42.8;133.3)	−19 (−66.8;55.1)	0.4374

TABLE E12. Dupilumab suppresses IgEs specific for a wide range of allergens in serum after 16 weeks of treatment

		Placebo qw (n = 27)		Dupilumab 200 mg qw (n = 27)	
Allergen-specific IgE	**n (%)[a]**	**Baseline median (Q1, Q3), kU/L**	**Median % change (Q1, Q3), kU/L**	**Baseline median (Q1, Q3), kU/L**	**Median % change (Q1, Q3), kU/L**
Cockroach, German	25 (46.3)	3 (0.7, 20.8)	23 (8.9, 30.8)	1 (0.3, 2.3)	-64 (−78.3, −18.5)*
Cladosporium	33 (61.1)	2 (0.8, 4.8)	36 (6.6, 65.4)	1 (0.4, 9.4)	−62 (−75.0, −33.1)*
Staph. enterotoxin A	39 (72.2)	1 (0.5, 2.1)	0 (−23.4, 26.8)	1 (0.3, 1.7)	−61 (−75.8, −50.4)**
Bermuda grass	41 (75.9)	4 (1.0, 34.7)	12 (−27.6, 82.3)	2 (0.7, 3.8)	−60 (−66.9, −39.9)**
Silver birch	41 (75.9)	27 (6.1, 56.5)	28 (−47.5, 130.0)	10 (0.5, 35.0)	−56 (−67.2, −41.8)*
Oak, white	37 (68.5)	15 (2.7, 38.7)	5 (−33.6, 51.4)	1 (0.3, 11.8)	−55 (−70.2, −39.8)**
Elm	39 (72.2)	4 (1.1, 16.9)	−10 (−41.2, 22.9)	1 (0.5, 4.5)	−54 (−66.7, −31.7)*
White ash	36 (66.7)	10 (1.2, 40.8)	31 (−36.1, 39.5)	1 (0.4, 16.2)	−53 (−65.4, −26.6)**
Johnson grass	42 (77.8)	6 (0.8, 14.1)	−9 (−30.4, 17.4)	1 (0.4, 1.9)	−52 (−71.6, −36.7)**
Cat dander	34 (63.0)	22 (3.5, 51.6)	−22 (−36.8, 0.0)	13 (2.2, 46.5)	−51 (−56.1, −33.3)*
Alder, grey	41 (75.9)	16 (2.0, 38.9)	27 (−35.0, 131.7)	7 (0.4, 22.4)	−50 (−70.3, −30.3)**
Timothy (Phleump.)	40 (74.1)	27 (1.7, 54.1)	21 (−7.7, 49.2)	1 (0.7, 7.5)	−50 (−66.7, −34.0)**
Sage mugwort	36 (66.7)	11 (0.8, 24.0)	−5 (−41.6, 0.0)	1 (0.5, 4.6)	−50 (−60.2, −12.2)#
Dog dander	36 (66.7)	25 (1.2, 95.8)	−1 (−31.8, 49.7)	11 (3.2, 54.5)	−49 (−63.0, −40.0)*
Alternaria tenius	35 (64.8)	1 (0.6, 5.3)	8 (0.0, 89.1)	1 (0.4, 4.3)	−46 (−61.5, −38.9)**
Ragweed	36 (66.7)	20 (4.7, 40.0)	−7 (−28.2, 0.0)	2 (0.8, 13.2)	−41 (−59.4, −32.4)*
Derm. farinae	39 (72.2)	63 (16.6, 200.0)	0 (0.0, 78.5)	66 (9.3, 200.0)	−39 (−63.1, −5.4)**
Staph. enterotoxin B	40 (74.1)	1 (0.4, 2.8)	−12 (−23.7, −1.7)	1 (0.2, 2.9)	−33 (−58.3, −22.8)*

[#]$P > 0.05$, *$P < 0.05$, **$P < 0.01$ vs placebo. Derm, dermatophagoides; Staph, staphylococcal.

[a] Number and percentage of patients positive (≥ 0.1 kU/L) for the allergen-specific IgEs at baseline; those not positive were excluded from analyses.